JP5138372B2 - 凍結乾燥血小板の調製法、凍結乾燥血小板を含む組成物、および使用法 - Google Patents
凍結乾燥血小板の調製法、凍結乾燥血小板を含む組成物、および使用法 Download PDFInfo
- Publication number
- JP5138372B2 JP5138372B2 JP2007525791A JP2007525791A JP5138372B2 JP 5138372 B2 JP5138372 B2 JP 5138372B2 JP 2007525791 A JP2007525791 A JP 2007525791A JP 2007525791 A JP2007525791 A JP 2007525791A JP 5138372 B2 JP5138372 B2 JP 5138372B2
- Authority
- JP
- Japan
- Prior art keywords
- platelets
- composition
- platelet
- lyophilized
- blood
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 238000000034 method Methods 0.000 title claims abstract description 330
- 239000000203 mixture Substances 0.000 title claims description 422
- 210000001772 blood platelet Anatomy 0.000 claims description 1485
- 239000008280 blood Substances 0.000 claims description 148
- 210000004369 blood Anatomy 0.000 claims description 147
- 238000011282 treatment Methods 0.000 claims description 127
- 230000023555 blood coagulation Effects 0.000 claims description 112
- 239000000872 buffer Substances 0.000 claims description 102
- 230000000694 effects Effects 0.000 claims description 90
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 64
- 150000001720 carbohydrates Chemical group 0.000 claims description 63
- 238000010438 heat treatment Methods 0.000 claims description 42
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 claims description 35
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 claims description 35
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 claims description 35
- 150000003839 salts Chemical class 0.000 claims description 26
- 239000003795 chemical substances by application Substances 0.000 claims description 24
- 238000000338 in vitro Methods 0.000 claims description 24
- 239000002577 cryoprotective agent Substances 0.000 claims description 23
- 238000005119 centrifugation Methods 0.000 claims description 20
- 238000007710 freezing Methods 0.000 claims description 15
- 230000008014 freezing Effects 0.000 claims description 15
- 239000003112 inhibitor Substances 0.000 claims description 15
- 230000002411 adverse Effects 0.000 claims description 14
- 229920000642 polymer Polymers 0.000 claims description 10
- 230000002401 inhibitory effect Effects 0.000 claims description 9
- 230000010118 platelet activation Effects 0.000 claims description 8
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 7
- 229930006000 Sucrose Natural products 0.000 claims description 7
- 238000000926 separation method Methods 0.000 claims description 7
- 239000005720 sucrose Substances 0.000 claims description 7
- BRLQWZUYTZBJKN-UHFFFAOYSA-N Epichlorohydrin Chemical compound ClCC1CO1 BRLQWZUYTZBJKN-UHFFFAOYSA-N 0.000 claims 3
- 230000008569 process Effects 0.000 abstract description 66
- 230000001225 therapeutic effect Effects 0.000 abstract description 25
- 238000011160 research Methods 0.000 abstract description 24
- 210000002381 plasma Anatomy 0.000 description 135
- 230000006870 function Effects 0.000 description 107
- 239000011859 microparticle Substances 0.000 description 98
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 94
- 206010053567 Coagulopathies Diseases 0.000 description 93
- 230000035602 clotting Effects 0.000 description 93
- 208000032843 Hemorrhage Diseases 0.000 description 82
- 208000027418 Wounds and injury Diseases 0.000 description 82
- 208000034158 bleeding Diseases 0.000 description 82
- 230000000740 bleeding effect Effects 0.000 description 82
- 208000009292 Hemophilia A Diseases 0.000 description 71
- 238000004108 freeze drying Methods 0.000 description 67
- 239000000306 component Substances 0.000 description 64
- 239000000126 substance Substances 0.000 description 63
- 206010052428 Wound Diseases 0.000 description 61
- 230000015271 coagulation Effects 0.000 description 55
- 238000005345 coagulation Methods 0.000 description 55
- 208000035475 disorder Diseases 0.000 description 51
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 50
- 208000031220 Hemophilia Diseases 0.000 description 48
- 230000007547 defect Effects 0.000 description 46
- 238000002474 experimental method Methods 0.000 description 44
- 241001465754 Metazoa Species 0.000 description 43
- 201000010099 disease Diseases 0.000 description 41
- 238000003556 assay Methods 0.000 description 39
- 210000004623 platelet-rich plasma Anatomy 0.000 description 39
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 37
- 239000007788 liquid Substances 0.000 description 37
- 238000001727 in vivo Methods 0.000 description 36
- 238000002360 preparation method Methods 0.000 description 36
- 108010054218 Factor VIII Proteins 0.000 description 33
- 102000001690 Factor VIII Human genes 0.000 description 33
- 208000014674 injury Diseases 0.000 description 33
- 108090000623 proteins and genes Proteins 0.000 description 32
- 239000003114 blood coagulation factor Substances 0.000 description 31
- 229960000301 factor viii Drugs 0.000 description 31
- 235000018102 proteins Nutrition 0.000 description 31
- 102000004169 proteins and genes Human genes 0.000 description 31
- 102000015081 Blood Coagulation Factors Human genes 0.000 description 29
- 108010039209 Blood Coagulation Factors Proteins 0.000 description 29
- 210000004027 cell Anatomy 0.000 description 28
- 239000003814 drug Substances 0.000 description 28
- 230000006378 damage Effects 0.000 description 27
- 229940079593 drug Drugs 0.000 description 27
- 239000002245 particle Substances 0.000 description 27
- 230000002950 deficient Effects 0.000 description 26
- 210000003743 erythrocyte Anatomy 0.000 description 26
- 238000011534 incubation Methods 0.000 description 26
- 239000000523 sample Substances 0.000 description 26
- 108010035532 Collagen Proteins 0.000 description 25
- 102000008186 Collagen Human genes 0.000 description 25
- 239000003146 anticoagulant agent Substances 0.000 description 25
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 25
- 229920001436 collagen Polymers 0.000 description 25
- 230000023597 hemostasis Effects 0.000 description 25
- 238000012544 monitoring process Methods 0.000 description 25
- 230000029663 wound healing Effects 0.000 description 25
- 229940030225 antihemorrhagics Drugs 0.000 description 24
- 230000007812 deficiency Effects 0.000 description 24
- 239000002874 hemostatic agent Substances 0.000 description 24
- 238000004519 manufacturing process Methods 0.000 description 24
- 238000002560 therapeutic procedure Methods 0.000 description 24
- 201000003542 Factor VIII deficiency Diseases 0.000 description 23
- 238000006243 chemical reaction Methods 0.000 description 23
- 238000001356 surgical procedure Methods 0.000 description 23
- 102100022641 Coagulation factor IX Human genes 0.000 description 22
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 22
- 230000027455 binding Effects 0.000 description 22
- 239000003153 chemical reaction reagent Substances 0.000 description 22
- 230000002776 aggregation Effects 0.000 description 21
- 238000004220 aggregation Methods 0.000 description 21
- 239000012503 blood component Substances 0.000 description 21
- 208000031169 hemorrhagic disease Diseases 0.000 description 21
- 238000001802 infusion Methods 0.000 description 21
- 239000000463 material Substances 0.000 description 21
- 239000011780 sodium chloride Substances 0.000 description 21
- 102100026735 Coagulation factor VIII Human genes 0.000 description 20
- 101000911390 Homo sapiens Coagulation factor VIII Proteins 0.000 description 20
- 210000004204 blood vessel Anatomy 0.000 description 20
- 229940127219 anticoagulant drug Drugs 0.000 description 19
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 18
- 239000008103 glucose Substances 0.000 description 18
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 17
- 229940098773 bovine serum albumin Drugs 0.000 description 17
- 238000012360 testing method Methods 0.000 description 17
- 239000007995 HEPES buffer Substances 0.000 description 16
- 230000015572 biosynthetic process Effects 0.000 description 16
- 239000008188 pellet Substances 0.000 description 16
- 108090000190 Thrombin Proteins 0.000 description 15
- 208000007536 Thrombosis Diseases 0.000 description 15
- 230000008901 benefit Effects 0.000 description 15
- 208000015294 blood coagulation disease Diseases 0.000 description 15
- 239000000243 solution Substances 0.000 description 15
- 210000001519 tissue Anatomy 0.000 description 15
- 230000008602 contraction Effects 0.000 description 14
- 239000008187 granular material Substances 0.000 description 14
- 238000011068 loading method Methods 0.000 description 14
- 229960004072 thrombin Drugs 0.000 description 14
- 108010076282 Factor IX Proteins 0.000 description 13
- 108010049003 Fibrinogen Proteins 0.000 description 13
- 102000008946 Fibrinogen Human genes 0.000 description 13
- 229960004222 factor ix Drugs 0.000 description 13
- 229940012952 fibrinogen Drugs 0.000 description 13
- 239000003102 growth factor Substances 0.000 description 13
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 12
- 239000012530 fluid Substances 0.000 description 12
- 230000002439 hemostatic effect Effects 0.000 description 12
- 230000004048 modification Effects 0.000 description 12
- 238000012986 modification Methods 0.000 description 12
- 150000003904 phospholipids Chemical class 0.000 description 12
- 238000011002 quantification Methods 0.000 description 12
- 230000009467 reduction Effects 0.000 description 12
- 230000008733 trauma Effects 0.000 description 12
- 108010014173 Factor X Proteins 0.000 description 11
- 108010074860 Factor Xa Proteins 0.000 description 11
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 11
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 11
- 102000002262 Thromboplastin Human genes 0.000 description 11
- 108010000499 Thromboplastin Proteins 0.000 description 11
- 230000004913 activation Effects 0.000 description 11
- 238000004458 analytical method Methods 0.000 description 11
- 201000007219 factor XI deficiency Diseases 0.000 description 11
- 208000009429 hemophilia B Diseases 0.000 description 11
- 239000012160 loading buffer Substances 0.000 description 11
- 229920003023 plastic Polymers 0.000 description 11
- 239000004033 plastic Substances 0.000 description 11
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 10
- 108010073385 Fibrin Proteins 0.000 description 10
- 102000009123 Fibrin Human genes 0.000 description 10
- 108091006905 Human Serum Albumin Proteins 0.000 description 10
- 102000008100 Human Serum Albumin Human genes 0.000 description 10
- 210000001367 artery Anatomy 0.000 description 10
- 235000014633 carbohydrates Nutrition 0.000 description 10
- 229950003499 fibrin Drugs 0.000 description 10
- 210000002950 fibroblast Anatomy 0.000 description 10
- 238000009472 formulation Methods 0.000 description 10
- 210000000265 leukocyte Anatomy 0.000 description 10
- 238000002156 mixing Methods 0.000 description 10
- 108090000672 Annexin A5 Proteins 0.000 description 9
- 102000004121 Annexin A5 Human genes 0.000 description 9
- 206010010356 Congenital anomaly Diseases 0.000 description 9
- 229920001612 Hydroxyethyl starch Polymers 0.000 description 9
- 239000012062 aqueous buffer Substances 0.000 description 9
- 230000036772 blood pressure Effects 0.000 description 9
- 239000012153 distilled water Substances 0.000 description 9
- 239000000499 gel Substances 0.000 description 9
- 229940050526 hydroxyethylstarch Drugs 0.000 description 9
- 229920001282 polysaccharide Polymers 0.000 description 9
- 102000009027 Albumins Human genes 0.000 description 8
- 108010088751 Albumins Proteins 0.000 description 8
- 102100023472 P-selectin Human genes 0.000 description 8
- 241000283984 Rodentia Species 0.000 description 8
- 208000013633 acquired hemophilia Diseases 0.000 description 8
- YZXBAPSDXZZRGB-DOFZRALJSA-N arachidonic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O YZXBAPSDXZZRGB-DOFZRALJSA-N 0.000 description 8
- 208000037765 diseases and disorders Diseases 0.000 description 8
- 210000003527 eukaryotic cell Anatomy 0.000 description 8
- 229920000669 heparin Polymers 0.000 description 8
- 230000001965 increasing effect Effects 0.000 description 8
- 230000037361 pathway Effects 0.000 description 8
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 8
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 8
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 8
- 108010013773 recombinant FVIIa Proteins 0.000 description 8
- 230000004044 response Effects 0.000 description 8
- 108010047303 von Willebrand Factor Proteins 0.000 description 8
- 102100036537 von Willebrand factor Human genes 0.000 description 8
- 229960001134 von willebrand factor Drugs 0.000 description 8
- 108010035766 P-Selectin Proteins 0.000 description 7
- 208000027276 Von Willebrand disease Diseases 0.000 description 7
- 239000007864 aqueous solution Substances 0.000 description 7
- 239000010836 blood and blood product Substances 0.000 description 7
- 208000011664 congenital factor XI deficiency Diseases 0.000 description 7
- 230000001419 dependent effect Effects 0.000 description 7
- 238000001514 detection method Methods 0.000 description 7
- 229940012426 factor x Drugs 0.000 description 7
- 230000001404 mediated effect Effects 0.000 description 7
- 102000005962 receptors Human genes 0.000 description 7
- 108020003175 receptors Proteins 0.000 description 7
- 239000007787 solid Substances 0.000 description 7
- 238000003860 storage Methods 0.000 description 7
- 208000012137 von Willebrand disease (hereditary or acquired) Diseases 0.000 description 7
- 241000283690 Bos taurus Species 0.000 description 6
- 241000282472 Canis lupus familiaris Species 0.000 description 6
- 108010054265 Factor VIIa Proteins 0.000 description 6
- 238000012413 Fluorescence activated cell sorting analysis Methods 0.000 description 6
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- 238000012404 In vitro experiment Methods 0.000 description 6
- 102100025306 Integrin alpha-IIb Human genes 0.000 description 6
- 241000699666 Mus <mouse, genus> Species 0.000 description 6
- 241000699670 Mus sp. Species 0.000 description 6
- 101000882917 Penaeus paulensis Hemolymph clottable protein Proteins 0.000 description 6
- 108010038512 Platelet-Derived Growth Factor Proteins 0.000 description 6
- 102000010780 Platelet-Derived Growth Factor Human genes 0.000 description 6
- 108010094028 Prothrombin Proteins 0.000 description 6
- 241000700159 Rattus Species 0.000 description 6
- 102000003790 Thrombin receptors Human genes 0.000 description 6
- 241000700605 Viruses Species 0.000 description 6
- 229930003448 Vitamin K Natural products 0.000 description 6
- 239000002253 acid Chemical class 0.000 description 6
- 230000009471 action Effects 0.000 description 6
- 230000010100 anticoagulation Effects 0.000 description 6
- 239000011575 calcium Substances 0.000 description 6
- 230000009852 coagulant defect Effects 0.000 description 6
- 239000012141 concentrate Substances 0.000 description 6
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 6
- 238000009826 distribution Methods 0.000 description 6
- 238000001035 drying Methods 0.000 description 6
- 229940012414 factor viia Drugs 0.000 description 6
- 230000014509 gene expression Effects 0.000 description 6
- 229960002897 heparin Drugs 0.000 description 6
- 239000002953 phosphate buffered saline Substances 0.000 description 6
- SHUZOJHMOBOZST-UHFFFAOYSA-N phylloquinone Natural products CC(C)CCCCC(C)CCC(C)CCCC(=CCC1=C(C)C(=O)c2ccccc2C1=O)C SHUZOJHMOBOZST-UHFFFAOYSA-N 0.000 description 6
- 239000003805 procoagulant Substances 0.000 description 6
- 239000000047 product Substances 0.000 description 6
- 230000000717 retained effect Effects 0.000 description 6
- 235000000346 sugar Nutrition 0.000 description 6
- 208000024891 symptom Diseases 0.000 description 6
- 206010043554 thrombocytopenia Diseases 0.000 description 6
- 230000017423 tissue regeneration Effects 0.000 description 6
- 235000019168 vitamin K Nutrition 0.000 description 6
- 239000011712 vitamin K Substances 0.000 description 6
- 150000003721 vitamin K derivatives Chemical class 0.000 description 6
- 229940046010 vitamin k Drugs 0.000 description 6
- UCTWMZQNUQWSLP-VIFPVBQESA-N (R)-adrenaline Chemical compound CNC[C@H](O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-VIFPVBQESA-N 0.000 description 5
- 229930182837 (R)-adrenaline Natural products 0.000 description 5
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 5
- 102100023804 Coagulation factor VII Human genes 0.000 description 5
- 229920002307 Dextran Polymers 0.000 description 5
- 108010023321 Factor VII Proteins 0.000 description 5
- 241000282326 Felis catus Species 0.000 description 5
- 241000282412 Homo Species 0.000 description 5
- 102000018697 Membrane Proteins Human genes 0.000 description 5
- 108010052285 Membrane Proteins Proteins 0.000 description 5
- 108010071390 Serum Albumin Proteins 0.000 description 5
- 230000005856 abnormality Effects 0.000 description 5
- 230000000702 anti-platelet effect Effects 0.000 description 5
- 239000003130 blood coagulation factor inhibitor Substances 0.000 description 5
- 229940125691 blood product Drugs 0.000 description 5
- 235000001465 calcium Nutrition 0.000 description 5
- 229910052791 calcium Inorganic materials 0.000 description 5
- 230000003247 decreasing effect Effects 0.000 description 5
- 238000003745 diagnosis Methods 0.000 description 5
- 238000002405 diagnostic procedure Methods 0.000 description 5
- 238000010790 dilution Methods 0.000 description 5
- 239000012895 dilution Substances 0.000 description 5
- 210000002889 endothelial cell Anatomy 0.000 description 5
- 229960005139 epinephrine Drugs 0.000 description 5
- 238000011156 evaluation Methods 0.000 description 5
- 229940012413 factor vii Drugs 0.000 description 5
- 230000002349 favourable effect Effects 0.000 description 5
- 239000010419 fine particle Substances 0.000 description 5
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 5
- 150000004676 glycans Chemical class 0.000 description 5
- 230000035876 healing Effects 0.000 description 5
- 230000001771 impaired effect Effects 0.000 description 5
- 230000003993 interaction Effects 0.000 description 5
- 230000006623 intrinsic pathway Effects 0.000 description 5
- 150000002632 lipids Chemical class 0.000 description 5
- 210000004185 liver Anatomy 0.000 description 5
- 239000003550 marker Substances 0.000 description 5
- 230000007246 mechanism Effects 0.000 description 5
- 230000000704 physical effect Effects 0.000 description 5
- 239000005017 polysaccharide Substances 0.000 description 5
- 230000008439 repair process Effects 0.000 description 5
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 5
- 239000006228 supernatant Substances 0.000 description 5
- 238000011269 treatment regimen Methods 0.000 description 5
- HAGOWCONESKMDW-FRSCJGFNSA-N (2s)-4-amino-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-amino-3-hydroxypropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]-4-methylpentanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]-4-oxobutanoic acid Chemical compound NC(N)=NCCC[C@@H](C(=O)N[C@@H](CC(N)=O)C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@@H](N)CO)CC1=CC=CC=C1 HAGOWCONESKMDW-FRSCJGFNSA-N 0.000 description 4
- 108010081589 Becaplermin Proteins 0.000 description 4
- 102000004506 Blood Proteins Human genes 0.000 description 4
- 108010017384 Blood Proteins Proteins 0.000 description 4
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 4
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 4
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 4
- 101001062153 Clostridium acetobutylicum (strain ATCC 824 / DSM 792 / JCM 1419 / LMG 5710 / VKM B-1787) Flavo-diiron protein FprA2 Proteins 0.000 description 4
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 4
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 4
- 102000004190 Enzymes Human genes 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 4
- 108010074864 Factor XI Proteins 0.000 description 4
- 108010080865 Factor XII Proteins 0.000 description 4
- 102000000429 Factor XII Human genes 0.000 description 4
- 229920001917 Ficoll Polymers 0.000 description 4
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 4
- 101710149643 Integrin alpha-IIb Proteins 0.000 description 4
- 229910019142 PO4 Inorganic materials 0.000 description 4
- 241001494479 Pecora Species 0.000 description 4
- 108091005804 Peptidases Proteins 0.000 description 4
- 102000035195 Peptidases Human genes 0.000 description 4
- 208000008425 Protein deficiency Diseases 0.000 description 4
- 102100027378 Prothrombin Human genes 0.000 description 4
- 229920002472 Starch Polymers 0.000 description 4
- 102000009618 Transforming Growth Factors Human genes 0.000 description 4
- 108010009583 Transforming Growth Factors Proteins 0.000 description 4
- 230000004520 agglutination Effects 0.000 description 4
- -1 amino phospholipids Chemical class 0.000 description 4
- 239000002246 antineoplastic agent Substances 0.000 description 4
- 210000000702 aorta abdominal Anatomy 0.000 description 4
- 229940114079 arachidonic acid Drugs 0.000 description 4
- 235000021342 arachidonic acid Nutrition 0.000 description 4
- 206010003549 asthenia Diseases 0.000 description 4
- 230000004071 biological effect Effects 0.000 description 4
- 229910001424 calcium ion Inorganic materials 0.000 description 4
- 230000000052 comparative effect Effects 0.000 description 4
- 229940127089 cytotoxic agent Drugs 0.000 description 4
- 230000007423 decrease Effects 0.000 description 4
- 238000011161 development Methods 0.000 description 4
- 230000018109 developmental process Effects 0.000 description 4
- 239000008121 dextrose Substances 0.000 description 4
- 230000007613 environmental effect Effects 0.000 description 4
- 229940088598 enzyme Drugs 0.000 description 4
- 239000012634 fragment Substances 0.000 description 4
- 230000002008 hemorrhagic effect Effects 0.000 description 4
- 230000001976 improved effect Effects 0.000 description 4
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 4
- 230000000670 limiting effect Effects 0.000 description 4
- 230000014759 maintenance of location Effects 0.000 description 4
- YDSWCNNOKPMOTP-UHFFFAOYSA-N mellitic acid Chemical compound OC(=O)C1=C(C(O)=O)C(C(O)=O)=C(C(O)=O)C(C(O)=O)=C1C(O)=O YDSWCNNOKPMOTP-UHFFFAOYSA-N 0.000 description 4
- 239000000546 pharmaceutical excipient Substances 0.000 description 4
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 4
- 239000008363 phosphate buffer Substances 0.000 description 4
- 229940039716 prothrombin Drugs 0.000 description 4
- 230000005855 radiation Effects 0.000 description 4
- 230000002829 reductive effect Effects 0.000 description 4
- 230000000284 resting effect Effects 0.000 description 4
- 230000028327 secretion Effects 0.000 description 4
- 210000002966 serum Anatomy 0.000 description 4
- 239000001509 sodium citrate Substances 0.000 description 4
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 4
- 239000008107 starch Substances 0.000 description 4
- 235000019698 starch Nutrition 0.000 description 4
- 108010063955 thrombin receptor peptide (42-47) Proteins 0.000 description 4
- KQTIIICEAUMSDG-UHFFFAOYSA-N tricarballylic acid Chemical compound OC(=O)CC(C(O)=O)CC(O)=O KQTIIICEAUMSDG-UHFFFAOYSA-N 0.000 description 4
- PJVWKTKQMONHTI-UHFFFAOYSA-N warfarin Chemical compound OC=1C2=CC=CC=C2OC(=O)C=1C(CC(=O)C)C1=CC=CC=C1 PJVWKTKQMONHTI-UHFFFAOYSA-N 0.000 description 4
- FHZSIZRTNHGLSX-FLMSMKGQSA-N (2s)-1-[(2s)-4-amino-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-amino-3-hydroxypropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]-4-methylpentanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]-4-oxobutanoyl]pyrrolidine-2-carboxyl Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CC(N)=O)C(=O)N1[C@@H](CCC1)C(O)=O)NC(=O)[C@@H](N)CO)C1=CC=CC=C1 FHZSIZRTNHGLSX-FLMSMKGQSA-N 0.000 description 3
- GMVPRGQOIOIIMI-UHFFFAOYSA-N (8R,11R,12R,13E,15S)-11,15-Dihydroxy-9-oxo-13-prostenoic acid Natural products CCCCCC(O)C=CC1C(O)CC(=O)C1CCCCCCC(O)=O GMVPRGQOIOIIMI-UHFFFAOYSA-N 0.000 description 3
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 3
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 3
- 208000001593 Bernard-Soulier syndrome Diseases 0.000 description 3
- 244000025254 Cannabis sativa Species 0.000 description 3
- 241000283707 Capra Species 0.000 description 3
- 241000282693 Cercopithecidae Species 0.000 description 3
- 101001062159 Clostridium acetobutylicum (strain ATCC 824 / DSM 792 / JCM 1419 / LMG 5710 / VKM B-1787) Flavo-diiron protein FprA1 Proteins 0.000 description 3
- 208000028702 Congenital thrombocyte disease Diseases 0.000 description 3
- 238000009007 Diagnostic Kit Methods 0.000 description 3
- 241000283086 Equidae Species 0.000 description 3
- 108010048049 Factor IXa Proteins 0.000 description 3
- 206010019663 Hepatic failure Diseases 0.000 description 3
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 3
- 206010028980 Neoplasm Diseases 0.000 description 3
- 241000283973 Oryctolagus cuniculus Species 0.000 description 3
- 102000007562 Serum Albumin Human genes 0.000 description 3
- 241000282887 Suidae Species 0.000 description 3
- 108090000166 Thrombin receptors Proteins 0.000 description 3
- 108091005605 Vitamin K-dependent proteins Proteins 0.000 description 3
- 230000002159 abnormal effect Effects 0.000 description 3
- 229960001138 acetylsalicylic acid Drugs 0.000 description 3
- 230000002378 acidificating effect Effects 0.000 description 3
- 239000013543 active substance Substances 0.000 description 3
- 239000000443 aerosol Substances 0.000 description 3
- 229960000711 alprostadil Drugs 0.000 description 3
- 239000003708 ampul Substances 0.000 description 3
- 230000033115 angiogenesis Effects 0.000 description 3
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 3
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 3
- 230000008827 biological function Effects 0.000 description 3
- 230000017531 blood circulation Effects 0.000 description 3
- 230000036770 blood supply Effects 0.000 description 3
- 201000011510 cancer Diseases 0.000 description 3
- 229910002091 carbon monoxide Inorganic materials 0.000 description 3
- 210000001715 carotid artery Anatomy 0.000 description 3
- 210000000170 cell membrane Anatomy 0.000 description 3
- 238000001516 cell proliferation assay Methods 0.000 description 3
- 230000001413 cellular effect Effects 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 239000000512 collagen gel Substances 0.000 description 3
- 230000000295 complement effect Effects 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 238000006911 enzymatic reaction Methods 0.000 description 3
- DEFVIWRASFVYLL-UHFFFAOYSA-N ethylene glycol bis(2-aminoethyl)tetraacetic acid Chemical compound OC(=O)CN(CC(O)=O)CCOCCOCCN(CC(O)=O)CC(O)=O DEFVIWRASFVYLL-UHFFFAOYSA-N 0.000 description 3
- 235000020650 eye health related herbal supplements Nutrition 0.000 description 3
- 239000000835 fiber Substances 0.000 description 3
- 239000011521 glass Substances 0.000 description 3
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 230000000977 initiatory effect Effects 0.000 description 3
- 208000007903 liver failure Diseases 0.000 description 3
- 231100000835 liver failure Toxicity 0.000 description 3
- 230000007774 longterm Effects 0.000 description 3
- 239000011159 matrix material Substances 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 239000001301 oxygen Substances 0.000 description 3
- 229910052760 oxygen Inorganic materials 0.000 description 3
- 239000000123 paper Substances 0.000 description 3
- 230000035790 physiological processes and functions Effects 0.000 description 3
- 239000000106 platelet aggregation inhibitor Substances 0.000 description 3
- 230000035755 proliferation Effects 0.000 description 3
- GMVPRGQOIOIIMI-DWKJAMRDSA-N prostaglandin E1 Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1CCCCCCC(O)=O GMVPRGQOIOIIMI-DWKJAMRDSA-N 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 230000011664 signaling Effects 0.000 description 3
- 239000011734 sodium Substances 0.000 description 3
- 241000894007 species Species 0.000 description 3
- 239000007921 spray Substances 0.000 description 3
- 150000008163 sugars Chemical class 0.000 description 3
- 230000001629 suppression Effects 0.000 description 3
- 230000009885 systemic effect Effects 0.000 description 3
- 108010093640 thrombin receptor peptide SFLLRNP Proteins 0.000 description 3
- RZWIIPASKMUIAC-VQTJNVASSA-N thromboxane Chemical compound CCCCCCCC[C@H]1OCCC[C@@H]1CCCCCCC RZWIIPASKMUIAC-VQTJNVASSA-N 0.000 description 3
- 231100000331 toxic Toxicity 0.000 description 3
- 230000002588 toxic effect Effects 0.000 description 3
- 238000002054 transplantation Methods 0.000 description 3
- 230000007998 vessel formation Effects 0.000 description 3
- PGOHTUIFYSHAQG-LJSDBVFPSA-N (2S)-6-amino-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-4-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-5-amino-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-5-amino-2-[[(2S)-1-[(2S,3R)-2-[[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-1-[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-amino-4-methylsulfanylbutanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-5-carbamimidamidopentanoyl]amino]propanoyl]pyrrolidine-2-carbonyl]amino]-3-methylbutanoyl]amino]-4-methylpentanoyl]amino]-4-methylpentanoyl]amino]acetyl]amino]-3-hydroxypropanoyl]amino]-4-methylpentanoyl]amino]-3-sulfanylpropanoyl]amino]-4-methylsulfanylbutanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-hydroxybutanoyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoyl]amino]-3-hydroxypropanoyl]amino]-3-hydroxypropanoyl]amino]-3-(1H-imidazol-5-yl)propanoyl]amino]-4-methylpentanoyl]amino]-3-hydroxybutanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-5-carbamimidamidopentanoyl]amino]-5-oxopentanoyl]amino]-3-hydroxybutanoyl]amino]-3-hydroxypropanoyl]amino]-3-carboxypropanoyl]amino]-3-hydroxypropanoyl]amino]-5-oxopentanoyl]amino]-5-oxopentanoyl]amino]-3-phenylpropanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-methylbutanoyl]amino]-4-methylpentanoyl]amino]-4-oxobutanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-4-carboxybutanoyl]amino]-5-oxopentanoyl]amino]hexanoic acid Chemical compound CSCC[C@H](N)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCCN)C(O)=O PGOHTUIFYSHAQG-LJSDBVFPSA-N 0.000 description 2
- CPKVUHPKYQGHMW-UHFFFAOYSA-N 1-ethenylpyrrolidin-2-one;molecular iodine Chemical compound II.C=CN1CCCC1=O CPKVUHPKYQGHMW-UHFFFAOYSA-N 0.000 description 2
- QZTKDVCDBIDYMD-UHFFFAOYSA-N 2,2'-[(2-amino-2-oxoethyl)imino]diacetic acid Chemical compound NC(=O)CN(CC(O)=O)CC(O)=O QZTKDVCDBIDYMD-UHFFFAOYSA-N 0.000 description 2
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Natural products CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 2
- 208000002004 Afibrinogenemia Diseases 0.000 description 2
- 206010002091 Anaesthesia Diseases 0.000 description 2
- 108010039627 Aprotinin Proteins 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 208000023275 Autoimmune disease Diseases 0.000 description 2
- 208000037157 Azotemia Diseases 0.000 description 2
- 239000005552 B01AC04 - Clopidogrel Substances 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 2
- 241000207199 Citrus Species 0.000 description 2
- 229940122295 Clotting factor inhibitor Drugs 0.000 description 2
- 206010067787 Coagulation factor deficiency Diseases 0.000 description 2
- 102000012422 Collagen Type I Human genes 0.000 description 2
- 108010022452 Collagen Type I Proteins 0.000 description 2
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 2
- SRBFZHDQGSBBOR-IOVATXLUSA-N D-xylopyranose Chemical compound O[C@@H]1COC(O)[C@H](O)[C@H]1O SRBFZHDQGSBBOR-IOVATXLUSA-N 0.000 description 2
- 108010000437 Deamino Arginine Vasopressin Proteins 0.000 description 2
- 206010016075 Factor I deficiency Diseases 0.000 description 2
- 108010080805 Factor XIa Proteins 0.000 description 2
- 102000003886 Glycoproteins Human genes 0.000 description 2
- 108090000288 Glycoproteins Proteins 0.000 description 2
- 108010000487 High-Molecular-Weight Kininogen Proteins 0.000 description 2
- 101001078143 Homo sapiens Integrin alpha-IIb Proteins 0.000 description 2
- 102000004877 Insulin Human genes 0.000 description 2
- 108090001061 Insulin Proteins 0.000 description 2
- 102100035792 Kininogen-1 Human genes 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 240000008821 Menyanthes trifoliata Species 0.000 description 2
- 235000011779 Menyanthes trifoliata Nutrition 0.000 description 2
- JOCBASBOOFNAJA-UHFFFAOYSA-N N-tris(hydroxymethyl)methyl-2-aminoethanesulfonic acid Chemical compound OCC(CO)(CO)NCCS(O)(=O)=O JOCBASBOOFNAJA-UHFFFAOYSA-N 0.000 description 2
- 240000004371 Panax ginseng Species 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 102000023159 Platelet Glycoprotein GPIb-IX Complex Human genes 0.000 description 2
- 108010045766 Platelet Glycoprotein GPIb-IX Complex Proteins 0.000 description 2
- 208000013544 Platelet disease Diseases 0.000 description 2
- 241000288906 Primates Species 0.000 description 2
- 239000004365 Protease Substances 0.000 description 2
- 208000001647 Renal Insufficiency Diseases 0.000 description 2
- 108010081391 Ristocetin Proteins 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- 208000026062 Tissue disease Diseases 0.000 description 2
- 108090000631 Trypsin Proteins 0.000 description 2
- 102000004142 Trypsin Human genes 0.000 description 2
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 2
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 2
- 206010047139 Vasoconstriction Diseases 0.000 description 2
- 238000010306 acid treatment Methods 0.000 description 2
- 239000012190 activator Substances 0.000 description 2
- 150000001298 alcohols Chemical class 0.000 description 2
- 230000037005 anaesthesia Effects 0.000 description 2
- 208000007502 anemia Diseases 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 229940088710 antibiotic agent Drugs 0.000 description 2
- 239000000729 antidote Substances 0.000 description 2
- 229940064804 betadine Drugs 0.000 description 2
- 239000012620 biological material Substances 0.000 description 2
- 210000000601 blood cell Anatomy 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 239000007853 buffer solution Substances 0.000 description 2
- 239000001110 calcium chloride Substances 0.000 description 2
- 229910001628 calcium chloride Inorganic materials 0.000 description 2
- 238000004364 calculation method Methods 0.000 description 2
- 239000001569 carbon dioxide Substances 0.000 description 2
- 229910002092 carbon dioxide Inorganic materials 0.000 description 2
- 230000002612 cardiopulmonary effect Effects 0.000 description 2
- 239000005018 casein Substances 0.000 description 2
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 2
- 235000021240 caseins Nutrition 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 230000024245 cell differentiation Effects 0.000 description 2
- 238000012512 characterization method Methods 0.000 description 2
- BGTFCAQCKWKTRL-YDEUACAXSA-N chembl1095986 Chemical compound C1[C@@H](N)[C@@H](O)[C@H](C)O[C@H]1O[C@@H]([C@H]1C(N[C@H](C2=CC(O)=CC(O[C@@H]3[C@H]([C@@H](O)[C@H](O)[C@@H](CO)O3)O)=C2C=2C(O)=CC=C(C=2)[C@@H](NC(=O)[C@@H]2NC(=O)[C@@H]3C=4C=C(C(=C(O)C=4)C)OC=4C(O)=CC=C(C=4)[C@@H](N)C(=O)N[C@@H](C(=O)N3)[C@H](O)C=3C=CC(O4)=CC=3)C(=O)N1)C(O)=O)=O)C(C=C1)=CC=C1OC1=C(O[C@@H]3[C@H]([C@H](O)[C@@H](O)[C@H](CO[C@@H]5[C@H]([C@@H](O)[C@H](O)[C@@H](C)O5)O)O3)O[C@@H]3[C@H]([C@@H](O)[C@H](O)[C@@H](CO)O3)O[C@@H]3[C@H]([C@H](O)[C@@H](CO)O3)O)C4=CC2=C1 BGTFCAQCKWKTRL-YDEUACAXSA-N 0.000 description 2
- 230000004087 circulation Effects 0.000 description 2
- 239000007979 citrate buffer Substances 0.000 description 2
- 235000020971 citrus fruits Nutrition 0.000 description 2
- GKTWGGQPFAXNFI-HNNXBMFYSA-N clopidogrel Chemical compound C1([C@H](N2CC=3C=CSC=3CC2)C(=O)OC)=CC=CC=C1Cl GKTWGGQPFAXNFI-HNNXBMFYSA-N 0.000 description 2
- 229940105778 coagulation factor viii Drugs 0.000 description 2
- 229960005188 collagen Drugs 0.000 description 2
- 238000012733 comparative method Methods 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 229940072645 coumadin Drugs 0.000 description 2
- 230000009089 cytolysis Effects 0.000 description 2
- 238000006731 degradation reaction Methods 0.000 description 2
- 229960004281 desmopressin Drugs 0.000 description 2
- NFLWUMRGJYTJIN-NXBWRCJVSA-N desmopressin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSCCC(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(N)=O)=O)CCC(=O)N)C1=CC=CC=C1 NFLWUMRGJYTJIN-NXBWRCJVSA-N 0.000 description 2
- 206010012601 diabetes mellitus Diseases 0.000 description 2
- 235000015872 dietary supplement Nutrition 0.000 description 2
- 238000001085 differential centrifugation Methods 0.000 description 2
- 230000003292 diminished effect Effects 0.000 description 2
- XEYBRNLFEZDVAW-ARSRFYASSA-N dinoprostone Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(O)=O XEYBRNLFEZDVAW-ARSRFYASSA-N 0.000 description 2
- IZEKFCXSFNUWAM-UHFFFAOYSA-N dipyridamole Chemical compound C=12N=C(N(CCO)CCO)N=C(N3CCCCC3)C2=NC(N(CCO)CCO)=NC=1N1CCCCC1 IZEKFCXSFNUWAM-UHFFFAOYSA-N 0.000 description 2
- 150000002016 disaccharides Chemical class 0.000 description 2
- 231100000673 dose–response relationship Toxicity 0.000 description 2
- 238000002651 drug therapy Methods 0.000 description 2
- 230000002255 enzymatic effect Effects 0.000 description 2
- 230000001747 exhibiting effect Effects 0.000 description 2
- 230000006624 extrinsic pathway Effects 0.000 description 2
- 230000012953 feeding on blood of other organism Effects 0.000 description 2
- 230000009477 glass transition Effects 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 238000005534 hematocrit Methods 0.000 description 2
- 230000036571 hydration Effects 0.000 description 2
- 238000006703 hydration reaction Methods 0.000 description 2
- 239000000017 hydrogel Substances 0.000 description 2
- BJRNKVDFDLYUGJ-RMPHRYRLSA-N hydroquinone O-beta-D-glucopyranoside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC=C(O)C=C1 BJRNKVDFDLYUGJ-RMPHRYRLSA-N 0.000 description 2
- 210000000987 immune system Anatomy 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 230000002458 infectious effect Effects 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 229940125396 insulin Drugs 0.000 description 2
- 230000010354 integration Effects 0.000 description 2
- 210000005061 intracellular organelle Anatomy 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 201000006370 kidney failure Diseases 0.000 description 2
- 238000000464 low-speed centrifugation Methods 0.000 description 2
- 238000004020 luminiscence type Methods 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 238000012792 lyophilization process Methods 0.000 description 2
- 239000011777 magnesium Substances 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 210000003593 megakaryocyte Anatomy 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 229910052751 metal Inorganic materials 0.000 description 2
- 239000002184 metal Substances 0.000 description 2
- 150000002772 monosaccharides Chemical class 0.000 description 2
- 238000010172 mouse model Methods 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- 108020004707 nucleic acids Proteins 0.000 description 2
- 102000039446 nucleic acids Human genes 0.000 description 2
- 150000007523 nucleic acids Chemical class 0.000 description 2
- 239000003960 organic solvent Substances 0.000 description 2
- 244000052769 pathogen Species 0.000 description 2
- WEXRUCMBJFQVBZ-UHFFFAOYSA-N pentobarbital Chemical compound CCCC(C)C1(CC)C(=O)NC(=O)NC1=O WEXRUCMBJFQVBZ-UHFFFAOYSA-N 0.000 description 2
- 239000010452 phosphate Substances 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 230000002947 procoagulating effect Effects 0.000 description 2
- 235000019833 protease Nutrition 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 229950004257 ristocetin Drugs 0.000 description 2
- 230000036573 scar formation Effects 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- 230000009870 specific binding Effects 0.000 description 2
- 210000000952 spleen Anatomy 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 239000008223 sterile water Substances 0.000 description 2
- 230000001954 sterilising effect Effects 0.000 description 2
- 150000005846 sugar alcohols Polymers 0.000 description 2
- 239000013589 supplement Substances 0.000 description 2
- 230000009469 supplementation Effects 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 230000035488 systolic blood pressure Effects 0.000 description 2
- 230000002123 temporal effect Effects 0.000 description 2
- PHWBOXQYWZNQIN-UHFFFAOYSA-N ticlopidine Chemical compound ClC1=CC=CC=C1CN1CC(C=CS2)=C2CC1 PHWBOXQYWZNQIN-UHFFFAOYSA-N 0.000 description 2
- 230000009261 transgenic effect Effects 0.000 description 2
- 239000012588 trypsin Substances 0.000 description 2
- 208000009852 uremia Diseases 0.000 description 2
- 230000025033 vasoconstriction Effects 0.000 description 2
- 229960005080 warfarin Drugs 0.000 description 2
- 238000013389 whole blood assay Methods 0.000 description 2
- IQVLXQGNLCPZCL-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) 2,6-bis[(2-methylpropan-2-yl)oxycarbonylamino]hexanoate Chemical compound CC(C)(C)OC(=O)NCCCCC(NC(=O)OC(C)(C)C)C(=O)ON1C(=O)CCC1=O IQVLXQGNLCPZCL-UHFFFAOYSA-N 0.000 description 1
- GOHPTLYPQCTZSE-UHFFFAOYSA-N 2,2-dimethylsuccinic acid Chemical compound OC(=O)C(C)(C)CC(O)=O GOHPTLYPQCTZSE-UHFFFAOYSA-N 0.000 description 1
- ZIIUUSVHCHPIQD-UHFFFAOYSA-N 2,4,6-trimethyl-N-[3-(trifluoromethyl)phenyl]benzenesulfonamide Chemical compound CC1=CC(C)=CC(C)=C1S(=O)(=O)NC1=CC=CC(C(F)(F)F)=C1 ZIIUUSVHCHPIQD-UHFFFAOYSA-N 0.000 description 1
- SAYBRQDMVZLOPM-UHFFFAOYSA-N 2-[(4-chlorophenyl)methylsulfanyl]acetic acid Chemical compound OC(=O)CSCC1=CC=C(Cl)C=C1 SAYBRQDMVZLOPM-UHFFFAOYSA-N 0.000 description 1
- YQPCHPBGAALCRT-UHFFFAOYSA-N 2-[1-(carboxymethyl)cyclohexyl]acetic acid Chemical compound OC(=O)CC1(CC(O)=O)CCCCC1 YQPCHPBGAALCRT-UHFFFAOYSA-N 0.000 description 1
- FWPVKDFOUXHOKQ-UHFFFAOYSA-N 2-[1-(carboxymethyl)cyclopentyl]acetic acid Chemical compound OC(=O)CC1(CC(O)=O)CCCC1 FWPVKDFOUXHOKQ-UHFFFAOYSA-N 0.000 description 1
- 125000000954 2-hydroxyethyl group Chemical group [H]C([*])([H])C([H])([H])O[H] 0.000 description 1
- IJRKANNOPXMZSG-SSPAHAAFSA-N 2-hydroxypropane-1,2,3-tricarboxylic acid;(2r,3s,4r,5r)-2,3,4,5,6-pentahydroxyhexanal Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O.OC(=O)CC(O)(C(O)=O)CC(O)=O IJRKANNOPXMZSG-SSPAHAAFSA-N 0.000 description 1
- GPICKHDXBPTBLD-UHFFFAOYSA-N 2-methylpropane-1,2,3-tricarboxylic acid Chemical compound OC(=O)CC(C)(CC(O)=O)C(O)=O GPICKHDXBPTBLD-UHFFFAOYSA-N 0.000 description 1
- ZOOGRGPOEVQQDX-UUOKFMHZSA-N 3',5'-cyclic GMP Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=C(NC2=O)N)=C2N=C1 ZOOGRGPOEVQQDX-UUOKFMHZSA-N 0.000 description 1
- OALHHIHQOFIMEF-UHFFFAOYSA-N 3',6'-dihydroxy-2',4',5',7'-tetraiodo-3h-spiro[2-benzofuran-1,9'-xanthene]-3-one Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC(I)=C(O)C(I)=C1OC1=C(I)C(O)=C(I)C=C21 OALHHIHQOFIMEF-UHFFFAOYSA-N 0.000 description 1
- DUHQIGLHYXLKAE-UHFFFAOYSA-N 3,3-dimethylglutaric acid Chemical compound OC(=O)CC(C)(C)CC(O)=O DUHQIGLHYXLKAE-UHFFFAOYSA-N 0.000 description 1
- HYRHLJWTFKJITA-UHFFFAOYSA-N 3-hydroxy-2-(hydroxymethyl)propanamide Chemical compound NC(=O)C(CO)CO HYRHLJWTFKJITA-UHFFFAOYSA-N 0.000 description 1
- 239000007991 ACES buffer Substances 0.000 description 1
- 208000030507 AIDS Diseases 0.000 description 1
- 208000028218 Acquired factor X deficiency Diseases 0.000 description 1
- 241000906543 Actaea racemosa Species 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 244000307697 Agrimonia eupatoria Species 0.000 description 1
- 244000291564 Allium cepa Species 0.000 description 1
- 235000002732 Allium cepa var. cepa Nutrition 0.000 description 1
- 240000002234 Allium sativum Species 0.000 description 1
- 241001116389 Aloe Species 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 239000005995 Aluminium silicate Substances 0.000 description 1
- 244000061520 Angelica archangelica Species 0.000 description 1
- 240000007087 Apium graveolens Species 0.000 description 1
- 235000015849 Apium graveolens Dulce Group Nutrition 0.000 description 1
- 235000010591 Appio Nutrition 0.000 description 1
- 240000003291 Armoracia rusticana Species 0.000 description 1
- 235000011330 Armoracia rusticana Nutrition 0.000 description 1
- 241000086254 Arnica montana Species 0.000 description 1
- 206010060964 Arterial haemorrhage Diseases 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 208000037260 Atherosclerotic Plaque Diseases 0.000 description 1
- 239000005528 B01AC05 - Ticlopidine Substances 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 208000019838 Blood disease Diseases 0.000 description 1
- BZUNJUAMQZRJIP-UHFFFAOYSA-N CPDA Natural products OCCCCCCCCCCCCCCC(O)=O BZUNJUAMQZRJIP-UHFFFAOYSA-N 0.000 description 1
- 235000007575 Calluna vulgaris Nutrition 0.000 description 1
- 235000002568 Capsicum frutescens Nutrition 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- GUBGYTABKSRVRQ-CUHNMECISA-N D-Cellobiose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-CUHNMECISA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 244000000626 Daucus carota Species 0.000 description 1
- 235000002206 Daucus carota subsp carota Nutrition 0.000 description 1
- 206010012689 Diabetic retinopathy Diseases 0.000 description 1
- 206010056340 Diabetic ulcer Diseases 0.000 description 1
- 101100108071 Dictyostelium discoideum act10 gene Proteins 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 241000283073 Equus caballus Species 0.000 description 1
- 206010016076 Factor II deficiency Diseases 0.000 description 1
- 206010016077 Factor IX deficiency Diseases 0.000 description 1
- 108010014172 Factor V Proteins 0.000 description 1
- 108010061932 Factor VIIIa Proteins 0.000 description 1
- 108010074105 Factor Va Proteins 0.000 description 1
- 108010071289 Factor XIII Proteins 0.000 description 1
- 108010000196 Factor XIIIa Proteins 0.000 description 1
- 108010071241 Factor XIIa Proteins 0.000 description 1
- 108010080379 Fibrin Tissue Adhesive Proteins 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 235000011201 Ginkgo Nutrition 0.000 description 1
- 235000008100 Ginkgo biloba Nutrition 0.000 description 1
- 244000194101 Ginkgo biloba Species 0.000 description 1
- 108010044091 Globulins Proteins 0.000 description 1
- 102000006395 Globulins Human genes 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- 240000004670 Glycyrrhiza echinata Species 0.000 description 1
- 235000001453 Glycyrrhiza echinata Nutrition 0.000 description 1
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 description 1
- 235000017382 Glycyrrhiza lepidota Nutrition 0.000 description 1
- 108060003393 Granulin Proteins 0.000 description 1
- 235000001287 Guettarda speciosa Nutrition 0.000 description 1
- 241001272567 Hominoidea Species 0.000 description 1
- 101000946124 Homo sapiens Lipocalin-1 Proteins 0.000 description 1
- 101000622137 Homo sapiens P-selectin Proteins 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 208000007646 Hypoprothrombinemias Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 208000026350 Inborn Genetic disease Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- AYRXSINWFIIFAE-SCLMCMATSA-N Isomaltose Natural products OC[C@H]1O[C@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)[C@@H](O)[C@@H](O)[C@@H]1O AYRXSINWFIIFAE-SCLMCMATSA-N 0.000 description 1
- 206010023203 Joint destruction Diseases 0.000 description 1
- 208000007766 Kaposi sarcoma Diseases 0.000 description 1
- YQEZLKZALYSWHR-UHFFFAOYSA-N Ketamine Chemical compound C=1C=CC=C(Cl)C=1C1(NC)CCCCC1=O YQEZLKZALYSWHR-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 240000005993 Lactuca saligna Species 0.000 description 1
- 235000003127 Lactuca serriola Nutrition 0.000 description 1
- 102100034724 Lipocalin-1 Human genes 0.000 description 1
- 102000003820 Lipoxygenases Human genes 0.000 description 1
- 108090000128 Lipoxygenases Proteins 0.000 description 1
- 206010067125 Liver injury Diseases 0.000 description 1
- 239000007993 MOPS buffer Substances 0.000 description 1
- 238000000134 MTT assay Methods 0.000 description 1
- 231100000002 MTT assay Toxicity 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 240000004658 Medicago sativa Species 0.000 description 1
- 235000017587 Medicago sativa ssp. sativa Nutrition 0.000 description 1
- 241000282579 Pan Species 0.000 description 1
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 description 1
- 235000003140 Panax quinquefolius Nutrition 0.000 description 1
- QGMRQYFBGABWDR-UHFFFAOYSA-M Pentobarbital sodium Chemical compound [Na+].CCCC(C)C1(CC)C(=O)NC(=O)[N-]C1=O QGMRQYFBGABWDR-UHFFFAOYSA-M 0.000 description 1
- 208000018262 Peripheral vascular disease Diseases 0.000 description 1
- 240000009164 Petroselinum crispum Species 0.000 description 1
- 102000015439 Phospholipases Human genes 0.000 description 1
- 108010064785 Phospholipases Proteins 0.000 description 1
- 108010000020 Platelet Factor 3 Proteins 0.000 description 1
- 108010035030 Platelet Membrane Glycoprotein IIb Proteins 0.000 description 1
- 241000219000 Populus Species 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- 102000004005 Prostaglandin-endoperoxide synthases Human genes 0.000 description 1
- 108090000459 Prostaglandin-endoperoxide synthases Proteins 0.000 description 1
- 108010029485 Protein Isoforms Proteins 0.000 description 1
- 102000001708 Protein Isoforms Human genes 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 241000124033 Salix Species 0.000 description 1
- 206010040943 Skin Ulcer Diseases 0.000 description 1
- 108010052164 Sodium Channels Proteins 0.000 description 1
- 102000018674 Sodium Channels Human genes 0.000 description 1
- 208000002847 Surgical Wound Diseases 0.000 description 1
- 244000223014 Syzygium aromaticum Species 0.000 description 1
- 235000016639 Syzygium aromaticum Nutrition 0.000 description 1
- 101000712605 Theromyzon tessulatum Theromin Proteins 0.000 description 1
- 229940122388 Thrombin inhibitor Drugs 0.000 description 1
- 206010043561 Thrombocytopenic purpura Diseases 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 101710162629 Trypsin inhibitor Proteins 0.000 description 1
- 229940122618 Trypsin inhibitor Drugs 0.000 description 1
- 244000274883 Urtica dioica Species 0.000 description 1
- 235000009108 Urtica dioica Nutrition 0.000 description 1
- 208000024248 Vascular System injury Diseases 0.000 description 1
- 208000012339 Vascular injury Diseases 0.000 description 1
- 206010047642 Vitiligo Diseases 0.000 description 1
- 206010048038 Wound infection Diseases 0.000 description 1
- 244000273928 Zingiber officinale Species 0.000 description 1
- 235000006886 Zingiber officinale Nutrition 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 210000000683 abdominal cavity Anatomy 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 210000003815 abdominal wall Anatomy 0.000 description 1
- 206010000210 abortion Diseases 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 208000030961 allergic reaction Diseases 0.000 description 1
- 235000011399 aloe vera Nutrition 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 235000012211 aluminium silicate Nutrition 0.000 description 1
- 206010002022 amyloidosis Diseases 0.000 description 1
- 230000003444 anaesthetic effect Effects 0.000 description 1
- 230000036592 analgesia Effects 0.000 description 1
- 230000003872 anastomosis Effects 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 230000002429 anti-coagulating effect Effects 0.000 description 1
- 230000000603 anti-haemophilic effect Effects 0.000 description 1
- 230000003302 anti-idiotype Effects 0.000 description 1
- 108010018823 anti-inhibitor coagulant complex Proteins 0.000 description 1
- 230000001147 anti-toxic effect Effects 0.000 description 1
- 238000009175 antibody therapy Methods 0.000 description 1
- 229940127090 anticoagulant agent Drugs 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 229940127218 antiplatelet drug Drugs 0.000 description 1
- 239000004019 antithrombin Substances 0.000 description 1
- 210000000709 aorta Anatomy 0.000 description 1
- 238000002617 apheresis Methods 0.000 description 1
- 230000004596 appetite loss Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 229960004405 aprotinin Drugs 0.000 description 1
- 239000003125 aqueous solvent Substances 0.000 description 1
- PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 description 1
- 229960000271 arbutin Drugs 0.000 description 1
- 229940090880 ardeparin Drugs 0.000 description 1
- 238000000149 argon plasma sintering Methods 0.000 description 1
- 230000001174 ascending effect Effects 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 238000005452 bending Methods 0.000 description 1
- 229940031422 benefix Drugs 0.000 description 1
- QNSOHXTZPUMONC-UHFFFAOYSA-N benzene pentacarboxylic acid Natural products OC(=O)C1=CC(C(O)=O)=C(C(O)=O)C(C(O)=O)=C1C(O)=O QNSOHXTZPUMONC-UHFFFAOYSA-N 0.000 description 1
- ZYGHJZDHTFUPRJ-UHFFFAOYSA-N benzo-alpha-pyrone Natural products C1=CC=C2OC(=O)C=CC2=C1 ZYGHJZDHTFUPRJ-UHFFFAOYSA-N 0.000 description 1
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 239000006177 biological buffer Substances 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 229960000074 biopharmaceutical Drugs 0.000 description 1
- 229920001222 biopolymer Chemical class 0.000 description 1
- 235000005770 birds nest Nutrition 0.000 description 1
- 229940019700 blood coagulation factors Drugs 0.000 description 1
- 238000004820 blood count Methods 0.000 description 1
- 239000003633 blood substitute Substances 0.000 description 1
- 244000078885 bloodborne pathogen Species 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 239000007975 buffered saline Substances 0.000 description 1
- RMRJXGBAOAMLHD-IHFGGWKQSA-N buprenorphine Chemical compound C([C@]12[C@H]3OC=4C(O)=CC=C(C2=4)C[C@@H]2[C@]11CC[C@]3([C@H](C1)[C@](C)(O)C(C)(C)C)OC)CN2CC1CC1 RMRJXGBAOAMLHD-IHFGGWKQSA-N 0.000 description 1
- 229960001736 buprenorphine Drugs 0.000 description 1
- GGAUUQHSCNMCAU-UHFFFAOYSA-N butane-1,2,3,4-tetracarboxylic acid Chemical compound OC(=O)CC(C(O)=O)C(C(O)=O)CC(O)=O GGAUUQHSCNMCAU-UHFFFAOYSA-N 0.000 description 1
- AXCZMVOFGPJBDE-UHFFFAOYSA-L calcium dihydroxide Chemical compound [OH-].[OH-].[Ca+2] AXCZMVOFGPJBDE-UHFFFAOYSA-L 0.000 description 1
- 239000000920 calcium hydroxide Substances 0.000 description 1
- 229910001861 calcium hydroxide Inorganic materials 0.000 description 1
- 159000000007 calcium salts Chemical class 0.000 description 1
- 238000011088 calibration curve Methods 0.000 description 1
- 210000002434 celiac artery Anatomy 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 238000002192 cholecystectomy Methods 0.000 description 1
- 235000005301 cimicifuga racemosa Nutrition 0.000 description 1
- 229960003009 clopidogrel Drugs 0.000 description 1
- 239000000701 coagulant Substances 0.000 description 1
- 208000014763 coagulation protein disease Diseases 0.000 description 1
- AGVAZMGAQJOSFJ-WZHZPDAFSA-M cobalt(2+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+2].N#[C-].[N-]([C@@H]1[C@H](CC(N)=O)[C@@]2(C)CCC(=O)NC[C@@H](C)OP(O)(=O)O[C@H]3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)\C2=C(C)/C([C@H](C\2(C)C)CCC(N)=O)=N/C/2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O AGVAZMGAQJOSFJ-WZHZPDAFSA-M 0.000 description 1
- 235000000125 common agrimony Nutrition 0.000 description 1
- 238000010835 comparative analysis Methods 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 239000000356 contaminant Substances 0.000 description 1
- 230000008094 contradictory effect Effects 0.000 description 1
- 239000013068 control sample Substances 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 210000004351 coronary vessel Anatomy 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 238000002316 cosmetic surgery Methods 0.000 description 1
- 235000001671 coumarin Nutrition 0.000 description 1
- 150000004775 coumarins Chemical class 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 229960004969 dalteparin Drugs 0.000 description 1
- 229960003828 danaparoid Drugs 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 239000002274 desiccant Substances 0.000 description 1
- 238000003795 desorption Methods 0.000 description 1
- 230000001627 detrimental effect Effects 0.000 description 1
- 229940039227 diagnostic agent Drugs 0.000 description 1
- 239000000032 diagnostic agent Substances 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- XPPKVPWEQAFLFU-UHFFFAOYSA-N diphosphoric acid Chemical compound OP(O)(=O)OP(O)(O)=O XPPKVPWEQAFLFU-UHFFFAOYSA-N 0.000 description 1
- 229960002768 dipyridamole Drugs 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 230000002183 duodenal effect Effects 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 229960000610 enoxaparin Drugs 0.000 description 1
- LKKJLUGBHZNOHT-UHFFFAOYSA-N ethanesulfonic acid;piperazine Chemical compound CCS(O)(=O)=O.CCS(O)(=O)=O.C1CNCCN1 LKKJLUGBHZNOHT-UHFFFAOYSA-N 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000004744 fabric Substances 0.000 description 1
- 229940105776 factor viii inhibitor bypassing activity Drugs 0.000 description 1
- 229940012444 factor xiii Drugs 0.000 description 1
- 239000012894 fetal calf serum Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 210000002683 foot Anatomy 0.000 description 1
- 229940087051 fragmin Drugs 0.000 description 1
- 230000005714 functional activity Effects 0.000 description 1
- 238000002825 functional assay Methods 0.000 description 1
- 238000011990 functional testing Methods 0.000 description 1
- 108010074605 gamma-Globulins Proteins 0.000 description 1
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 description 1
- 235000004611 garlic Nutrition 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 238000001415 gene therapy Methods 0.000 description 1
- 208000016361 genetic disease Diseases 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 235000008397 ginger Nutrition 0.000 description 1
- 235000008434 ginseng Nutrition 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 201000011066 hemangioma Diseases 0.000 description 1
- 208000014951 hematologic disease Diseases 0.000 description 1
- 208000018706 hematopoietic system disease Diseases 0.000 description 1
- 231100000753 hepatic injury Toxicity 0.000 description 1
- 229920006158 high molecular weight polymer Polymers 0.000 description 1
- 210000001624 hip Anatomy 0.000 description 1
- 230000000887 hydrating effect Effects 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000002163 immunogen Effects 0.000 description 1
- 230000009851 immunogenic response Effects 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 238000002991 immunohistochemical analysis Methods 0.000 description 1
- 230000006057 immunotolerant effect Effects 0.000 description 1
- 238000000099 in vitro assay Methods 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 229910052738 indium Inorganic materials 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- ZPNFWUPYTFPOJU-LPYSRVMUSA-N iniprol Chemical compound C([C@H]1C(=O)NCC(=O)NCC(=O)N[C@H]2CSSC[C@H]3C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(N[C@H](C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC=4C=CC=CC=4)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC=4C=CC=CC=4)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC2=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H]2N(CCC2)C(=O)[C@@H](N)CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N2[C@@H](CCC2)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N2[C@@H](CCC2)C(=O)N3)C(=O)NCC(=O)NCC(=O)N[C@@H](C)C(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@H](C(=O)N1)C(C)C)[C@@H](C)O)[C@@H](C)CC)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 ZPNFWUPYTFPOJU-LPYSRVMUSA-N 0.000 description 1
- 229940095443 innohep Drugs 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 230000006525 intracellular process Effects 0.000 description 1
- 230000004068 intracellular signaling Effects 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 239000002555 ionophore Substances 0.000 description 1
- 230000000236 ionophoric effect Effects 0.000 description 1
- 210000004153 islets of langerhan Anatomy 0.000 description 1
- DLRVVLDZNNYCBX-RTPHMHGBSA-N isomaltose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)C(O)O1 DLRVVLDZNNYCBX-RTPHMHGBSA-N 0.000 description 1
- 210000001503 joint Anatomy 0.000 description 1
- 230000009916 joint effect Effects 0.000 description 1
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
- 229960003299 ketamine Drugs 0.000 description 1
- 208000017169 kidney disease Diseases 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 231100000518 lethal Toxicity 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 229940010454 licorice Drugs 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 230000005976 liver dysfunction Effects 0.000 description 1
- 244000144972 livestock Species 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- 235000021266 loss of appetite Nutrition 0.000 description 1
- 208000019017 loss of appetite Diseases 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 229940118179 lovenox Drugs 0.000 description 1
- 239000003055 low molecular weight heparin Substances 0.000 description 1
- 229940127215 low-molecular weight heparin Drugs 0.000 description 1
- 239000008176 lyophilized powder Substances 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 239000003595 mist Substances 0.000 description 1
- 239000003226 mitogen Substances 0.000 description 1
- 230000002297 mitogenic effect Effects 0.000 description 1
- 230000000877 morphologic effect Effects 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- GISJHCLTIVIGLX-UHFFFAOYSA-N n-[4-[(4-chlorophenyl)methoxy]pyridin-2-yl]-2-(2,6-difluorophenyl)acetamide Chemical compound FC1=CC=CC(F)=C1CC(=O)NC1=CC(OCC=2C=CC(Cl)=CC=2)=CC=N1 GISJHCLTIVIGLX-UHFFFAOYSA-N 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 229940105631 nembutal Drugs 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- BJRNKVDFDLYUGJ-UHFFFAOYSA-N p-hydroxyphenyl beta-D-alloside Natural products OC1C(O)C(O)C(CO)OC1OC1=CC=C(O)C=C1 BJRNKVDFDLYUGJ-UHFFFAOYSA-N 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000007918 pathogenicity Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 229960001412 pentobarbital Drugs 0.000 description 1
- 235000011197 perejil Nutrition 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 229940090007 persantine Drugs 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 229940020573 plavix Drugs 0.000 description 1
- 229960001109 policosanol Drugs 0.000 description 1
- 229920002959 polymer blend Polymers 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 230000002980 postoperative effect Effects 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 159000000001 potassium salts Chemical class 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 238000002203 pretreatment Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 1
- KCXFHTAICRTXLI-UHFFFAOYSA-N propane-1-sulfonic acid Chemical compound CCCS(O)(=O)=O KCXFHTAICRTXLI-UHFFFAOYSA-N 0.000 description 1
- 239000003380 propellant Substances 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 238000000159 protein binding assay Methods 0.000 description 1
- 235000004252 protein component Nutrition 0.000 description 1
- 231100000654 protein toxin Toxicity 0.000 description 1
- 229940024790 prothrombin complex concentrate Drugs 0.000 description 1
- 108010014806 prothrombinase complex Proteins 0.000 description 1
- 229940005657 pyrophosphoric acid Drugs 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- 230000000171 quenching effect Effects 0.000 description 1
- 229940068953 recombinant fviia Drugs 0.000 description 1
- 238000010188 recombinant method Methods 0.000 description 1
- 238000003168 reconstitution method Methods 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 238000011946 reduction process Methods 0.000 description 1
- 230000011514 reflex Effects 0.000 description 1
- 238000005057 refrigeration Methods 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 229940116157 regranex Drugs 0.000 description 1
- 239000000310 rehydration solution Substances 0.000 description 1
- 230000002787 reinforcement Effects 0.000 description 1
- 210000002254 renal artery Anatomy 0.000 description 1
- 230000008521 reorganization Effects 0.000 description 1
- 238000002271 resection Methods 0.000 description 1
- 208000037803 restenosis Diseases 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 239000000565 sealant Substances 0.000 description 1
- 229940048730 senega Drugs 0.000 description 1
- 102000035025 signaling receptors Human genes 0.000 description 1
- 108091005475 signaling receptors Proteins 0.000 description 1
- 231100000019 skin ulcer Toxicity 0.000 description 1
- 229940126586 small molecule drug Drugs 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 210000004872 soft tissue Anatomy 0.000 description 1
- 235000021055 solid food Nutrition 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 238000012453 sprague-dawley rat model Methods 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 230000010473 stable expression Effects 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 238000000859 sublimation Methods 0.000 description 1
- 230000008022 sublimation Effects 0.000 description 1
- 238000005092 sublimation method Methods 0.000 description 1
- 230000000153 supplemental effect Effects 0.000 description 1
- 230000001502 supplementing effect Effects 0.000 description 1
- 230000026676 system process Effects 0.000 description 1
- 239000008399 tap water Substances 0.000 description 1
- 235000020679 tap water Nutrition 0.000 description 1
- 210000002435 tendon Anatomy 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 238000010257 thawing Methods 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 238000011287 therapeutic dose Methods 0.000 description 1
- 239000003868 thrombin inhibitor Substances 0.000 description 1
- 239000003634 thrombocyte concentrate Substances 0.000 description 1
- 230000001732 thrombotic effect Effects 0.000 description 1
- 229940028869 ticlid Drugs 0.000 description 1
- 229960005001 ticlopidine Drugs 0.000 description 1
- 230000001550 time effect Effects 0.000 description 1
- SYRHIZPPCHMRIT-UHFFFAOYSA-N tin(4+) Chemical compound [Sn+4] SYRHIZPPCHMRIT-UHFFFAOYSA-N 0.000 description 1
- 229960005062 tinzaparin Drugs 0.000 description 1
- 210000003371 toe Anatomy 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 108700012359 toxins Proteins 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- 229940108519 trasylol Drugs 0.000 description 1
- 230000000472 traumatic effect Effects 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 239000002753 trypsin inhibitor Substances 0.000 description 1
- 210000003606 umbilical vein Anatomy 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 235000005765 wild carrot Nutrition 0.000 description 1
- 239000003357 wound healing promoting agent Substances 0.000 description 1
- BPICBUSOMSTKRF-UHFFFAOYSA-N xylazine Chemical compound CC1=CC=CC(C)=C1NC1=NCCCS1 BPICBUSOMSTKRF-UHFFFAOYSA-N 0.000 description 1
- 229960001600 xylazine Drugs 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N1/00—Preservation of bodies of humans or animals, or parts thereof
- A01N1/02—Preservation of living parts
- A01N1/0278—Physical preservation processes
- A01N1/0284—Temperature processes, i.e. using a designated change in temperature over time
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N1/00—Preservation of bodies of humans or animals, or parts thereof
- A01N1/02—Preservation of living parts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/19—Platelets; Megacaryocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/86—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood coagulating time or factors, or their receptors
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Hematology (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Zoology (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Medicinal Chemistry (AREA)
- Dentistry (AREA)
- Molecular Biology (AREA)
- Environmental Sciences (AREA)
- Wood Science & Technology (AREA)
- Urology & Nephrology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Microbiology (AREA)
- Diabetes (AREA)
- Developmental Biology & Embryology (AREA)
- Virology (AREA)
- Epidemiology (AREA)
- Dermatology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Description
本出願は、下記の特許出願の開示に依存し、該出願の登録日付の利益を主張する。なお、これら出願全ての開示全体を引用することにより本出願に含める。すなわち、2004年8月12日登録米国仮出願第60/600,838号、2004年10月20日登録米国仮出願第60/619,930号、2005年6月15日登録米国特許出願第11/152,774号、および2005年8月5日登録米国特許出願第11/197,310号である。
本発明は、血液および血液製品の分野に関する。より詳細には、本発明は、血小板および血小板組成物、特に、凍結乾燥血小板、または、再水和凍結乾燥血小板を含む組成物であって、治療(処置)、診断、および研究目的に有用な組成物に関する。
ここで、本発明の様々な例示の実施態様について詳細に参照する。なお、実施例が付属の図面に具体的に示される。
凍結乾燥血小板の調製
凍結乾燥血小板の調製
本発明の組成物の調製
凍結乾燥血小板製造のための別法
漸増微粒子パーセントを有する凍結乾燥血小板の別の製造法
凍結乾燥血小板製造のために従来技術で用いられる方法の比較例
実施例2に従って調製された凍結乾燥血小板の特性解明
凍結乾燥血小板のサイズおよび顆粒状態に及ぼす凍結乾燥後加熱工程の作用
他の方法と比較した場合の、凍結乾燥後熱処理の凍結乾燥血小板のサイズに及ぼす作用
実施例2に従って調製された凍結乾燥血小板の生物学的活性の解明
再構成時の血小板表面マーカーの特性解明
異性形 BD PharminagenマウスIgGカッパ
HLA BD Pharminagen抗ヒトHLA-B-C
GPIb DakoCytomationマウス抗ヒトCD24bクローンAN51
IIbIIIa DakoCytomationマウス抗ヒトCD41クローン5b12
P-セレクチン BD Pharminagen抗ヒトCD62P(カタログ番号555523)
サッカライド負荷バッファーおよび凍結乾燥バッファーにおけるエタノールの作用
HLA低減
細胞による増殖アッセイ
コラーゲン-線維芽細胞収縮アッセイ
組成物の物理的特性の評価
凍結乾燥血小板の凝固機能
図13Aに示すデータは下記のようにして得た。凝固時間は、100 ulのAPCT(活性化血漿凝固時間、Analytical Control Systems, Inc., Fischers, インディアナ州)試薬を、様々な調製品FDP-1、FDP-2、またはFDP-3から得られた、各種濃度の水再構成凍結乾燥血小板25 ul、および、市販の業者から購入した因子欠乏血漿25 ulと混合した。この混合物を、水浴において37℃で3分インキュベートし、次に100 ulの0.02M CaCl2 (37℃)を加え、凝固時間を定量した。
本発明の組成物によるインビボ実験
インビボ特性のさらに別の分析
傷口閉鎖測度および複数投与の評価
創傷閉鎖速度および、期限内および期限外血小板単回投与の評価
本発明の組成物用送達システム
組成物の物理的特性の評価
正常血漿プール用較正試薬としての凍結乾燥血小板の使用
血小板欠乏血漿用較正試薬としての凍結乾燥血小板の使用
凝固因子欠損に対する診断試薬としての凍結乾燥血小板の使用
特異的凝固因子欠損を特定するための診断ツールとしての凍結乾燥血小板の使用
凍結乾燥血小板は、全血に対し明瞭な反応プロフィールを示す。
ビタミンK依存性凝固因子を監視するための凍結乾燥血小板の使用
血小板欠陥を特定するための診断試薬としての凍結乾燥血小板の使用
擬似血友病Cの誘発および血小板による治療
擬似血友病Bの誘発および血小板による治療
阻害剤による後天的血友病の誘発および血小板による治療
血小板による血友病決の治療
アプロチニンによる凝固欠陥の誘発および血小板による治療
ヘパリンによる凝固欠陥(薬剤誘発凝固障害)の誘発および血小板による治療
血小板の組み換えVIIa因子に及ぼす作用
本発明の血小板に対するアネキシンVの結合
クリステンソン、ジェイ・ティー(Christenson, JT)、エイ、カランゴス(A. Kalangos)「上行大動脈手術における、血小板によって強化された自己由来フィブリン糊」、Thorac. Cardiovasc. Surg., 52, 225-229頁(2004)
ギルバート、ジー・イー(Gilbert, GE), ピー・ジェイ、シムズ(PJ. Sims)、ティー、ウィードマー(T. Wiedmer)、ビー、フューリー(B. Furie)、ビー・シー、フューリー(BC. Furie)、エス・ジェイ、シャッティル(SJ. Shattil)「血小板由来微粒子は、VIII因子に対し高い親和性を持つ受容体を発現する」J. Biol. Chem. 266, 17261-17268頁(1991)
ジャイルス、エイ・アール(Giles, AR)、マン、ケイ・ジー(Mann, KG)、ネシャイム、エム・イー(Nesheim, ME)「Xa因子およびフォスファチジルコリン-フォスファチジルセリン顆粒の結合体は、インビボにおいてVIII因子を迂回する」Br. J. Haematol. 69(4)、8月号(1988)
ホフマン、エム(Hoffman, M)、ディー・エム、モンロー(DM. Monroe)、エイチ・アール、ロバーツ(HR. Roberts)「活性化血小板および血小板由来微粒子に対する凝固因子IXaの結合:フローサイトメトリー実験」Thromb. Haemast., 68, 74-78頁(1992)
ホーム、ピー・エイ(Holme, PA), エフ、ブロスタッド(F. Brosstad)、エヌ・オー、ソラム(NO. Solum)「血小板由来微粒子および活性化血小板はXa因子活性を発現する」Blood Coagul. Fibrinolysis, 6, 302-310頁(1995)
フラコビノーバ、アイ(Hrachovinova, I)、カンビアン、ビー(Cambien, B)、ハフェジモガダム、エイ(HafeziMoghadam, A)、カッペルマイヤー、ジェイ(Kappelmayer, J)、カンプハウゼン、アール・ティー(Camphausen, RT)、ウィーダム、エイ(Widom, A)、ジア、エル(Xia, L)、カザジアン、エイチ・エイチ二世(Kazazian, HH. Jr.)、シャウプ、アール・ジー(Schaub, RG)、マッキーバー、アール・ピー(McEver, RP)、ワグナー、ディー・ディー(Wagner, DD)「PセレクチンとPSGL1の相互作用は、マウスの血友病Aモデルにおいて止血機構を矯正する微粒子を生成する」、Nat. Med. 9(8)、1025頁、8月号(2003)
キルビー、シー・ジェイ(Kirby, CJ)、グレゴリアディス、ジー(Gregoriadis, G)、「血友病の経口治療のためのVIII因子含有リポソームの調製」、J. Microencapsul. 1(1)、3345頁、1-3月号(1984)
マツッコ、エル(Mazzucco, L)、ディー、メディチ(D, Medici)、エム、セラ(M. Serra)、アール、パニツァ(R. Panizza)、ジー、リヴァラ(G. Rivara)、エス、オレッチア(S. Orecchia)、アール、リベナー(R. Libener)、イー、カタナ(E. Catana)、エイ、レーヴィス(A. Levis)、ピー・ジー、ベッタ(PG. Betta)、ピー、ボルツィーニ(P. Borzini)、「難治性創傷を治療するための、自己由来血小板ゲルの使用−パイロット実験」、Transfusion, 44, 1013-1018頁(2004)
ニューランド、アール(Nieuwland, R)、アール・ジェイ、バークマンズ(RJ. Berckmans)、アール・シー、ロッテヴィール-エイクマン(RC. Rotteveel-Eijkman)、ケー・エヌ、マケリン(KN. Maquelin)、ケー・ジェイ、ローゼンダール(KJ. Roozendaal)、ケー、テンヘイヴ(K. ten Have)、エル、エイスマン(L. Eijsman)、シー・イー、ハック(CE. Hack)、エイ、スターク(A. Sturk)、「心肺バイパス中に患者に生成される細胞由来微粒子は極めて凝固促進性である」、Circulation, 96, 3534-3541頁(1997)
オイカリネン、ケー・エス(Oikarinen, KS)、ジー・ケー、サンダー(GK. Sandor)、ヴィー・ティー、カイヌライネン(VT. Kainulainen)、エム、サロネン-ケンピ(M. Salonen-Kemppi)、「歯科用インプラント設置促進のための、狭い外傷を被った前方歯槽***の増量」、Dent. Traumatol. 19, 19-29頁(2003)
ピアス、ジー・エフ(Pierce, GF)、ティー・エイ、マストー(TA. Mustoe)、ジェイ、リンゲルバック(J. Lingelbach)、ヴィー・アール、マサコウスキー(VR. Masakowski)、ジー・エル、グリフィン(GL. Griffin)、アール・エム、シニア(RM. Senior)、テイー・エフ、デュエル(TF. Deuel)、「血小板由来増殖因子および変換増殖因子ベータは、特異な機構によって組織修復活性を強化する」、J. Cell Biol., 109, 429-440頁(1989)
プライアー、ジェイ・ジェイ(Prior, JJ)、ディー・ジー、ウォラス(DG. Wallace)、エイ、ハフナー(A. Hafner)、エヌ、パワーズ(N. Powers)、「繊維性コラーゲン、ウシ・トロンビン、および自己由来血漿を含む噴霧可能な止血剤」、Ann. Thorac. Surg., 68, 479-485頁(1999)
ロージング、ジェイ(Rosing, J)、イー・エム、ビーバーズ(EM. Bevers)、ピー、コンフリュース(P. Comfurius)、エイチ・シー、ヘンカー(HC. Hemker)、ジー・ヴァン、ディエイジェン(G van Dieijen)、エイチ・ジェイ、ワイス(HJ. Weiss)、アール・エフ、ツヴァール(RF. Zwaal)、「出血障害を抱える患者から得た血小板におけるリン脂質暴露低減に関連するX因子およびプロトロンビン活性化の損失」、Blood, 65, 1557-1561頁(1985)
セレブラーニィ、ヴィー・エル(Serebruany, VL)、ジェイ・ヴィー、オルドネス(JV. Ordonez)、ヴィー・ヴィー、ユロフスキー(VV. Yurovsky)、ピー・エイ、ガーベル(PA. Gurbel)、「ヒト対ブタ血小板表面抗原の交差反応性は、糖タンパクIbおよびIIIaの間では近似するが、糖タンパクIIb/IIIa複合体ではそうはならない」、J. Thromb. Thrombolysis., 5, 37-41頁(1998)
シムズ、ピー・ジェイ(Sims, PJ)、イー・エム、ファイオーニ(EM. Faioni)、ティー、ウィードマー(T. Wiedmer)、エス・ジェイ、シャッティル(SJ. Shattil)、「補体タンパクC5b-9は、凝固因子Vaに対する膜受容体の濃縮された血小板表面から膜顆粒の放出を引き起こし、プロトロンビナーゼ活性を発現する」、J. Biol. Chem. 263, 18205-18212頁(1988)
シムズ、ピー・ジェイ(Sims, PJ)、エス・エイ、ローリンズ(SA. Rollins)、ティー、ウィードマー(T. Wiedmer)、「血小板上の補体の調節的制御。C5b-9複合体の膜抑制因子による血小板の凝固促進反応の修飾」、J. Biol. Chem. 264, 19228-19235頁(1989)
スティード、ディー・エル(Steed, DL)、「創傷治癒における増殖因子の役割」、Surg. Clin. North Am., 77, 575-586頁(1997)
タンズ、ジー(Tans, G)、ジェイ、ロージング(J. Rosing)、エム・シー、トマッセン(MC. Thomassen)、エム・ジェイ、ヘーブ(MJ. Heeb)、アール・エフ、ツヴァール(RF. Zwaal)、ジェイ・エイチ、グリフィン(JH. Griffin)、「刺激された、血小板および血小板由来微粒子の抗凝固および凝固促進活性の比較」、Blood, 77, 2641-2648頁(1991)
ウェイジョン、ピー(Wajon, P)、ジェイ、ギブソン(J. Gibson)、シー、ヒューズ(C. Hughes)、ビー、スリフト(B. Thrift)、「術中血漿瀉血および自己由来血小板ゲルは、胸部チューブ排出を低減しない、または冠状動脈バイパス移植片設置再手術後の異種血液輸血を低減しない」、Anesth. Analg., 93, 536-542頁(2001)
ヤロヴォイ、エイチ・ヴィー(Yarovoi, HV)、カフリン、ディー(Kufrin, D)、エスリン、ディー・イー(Eslin, DE)、ソーントン、エム・エイ(Thornton, MA)、ハーベリヒター、エス・エル(Haberichter, SL)、シー、キュー(Shi, Q)、ジュー、エイチ(Zhu, H)、カミール、アール(Camire, R)、ファカラザデー、エス・エス(Fakarazadeh, SS)、コワルスカ、エム・エイ(Kowalska, MA)、ウィルコックス、ディー・エイ(Wilcox, DA)、サケイス、ビー・エス(Sachais, BS)、モンゴメリー、アール・アール(Montgomery, PR)、ポンス、エム(Poncz, M)、「血小板局外に発現されたVIII因子:血友病A治療における有効性」、Blood, 100(2), 400613頁、12月1日、2003年
本明細書に引用された文献は全て、参照することによりその全体を本明細書に含める。
Claims (17)
- 凍結乾燥血小板であって、
血小板を準備すること;
少なくとも1種のサッカライドを含む塩バッファーに該血小板を懸濁し、第1組成物を作製すること;
該少なくとも1種のサッカライドが血小板と接触するのに少なくとも十分な時間、第1組成物を、凍結点を超える温度でインキュベートすること;
寒冷保護剤を添加して第2組成物を作製すること、
但し、第1組成物は、寒冷保護剤が添加されるまでは、遠心、またはその他の分離工程を受けることはなく、かつ第1組成物、第2組成物またはその両者は血小板活性化阻害剤を含まない;および、
第2組成物を凍結乾燥して凍結乾燥血小板を作製すること、
を含む方法によって作製される前記凍結乾燥血小板。 - 前記血小板は室温で少なくとも6ヶ月安定であることを特徴とする、請求項1の凍結乾燥血小板。
- 請求項1又は2に記載の凍結乾燥血小板を再水和して得た再水和血小板であって、新鮮血小板と事実上同じサイズと顆粒状態を持つことを特徴とする、再水和血小板。
- 前記血小板は、さらにショ糖とエピクロロヒドリンとを共重合させることによって得られるポリマーであって、平均分子量が400,000である前記ポリマーを含む組成物中に存在することを特徴とする、請求項3の再水和血小板。
- 前記血小板は活性化されないことを特徴とする、請求項3又は4に記載の再水和血小板。
- 前記再水和血小板は、渦巻き特性を示す請求項3から5の何れか1項に記載の再水和血小板。
- (a)請求項1又は2に記載の凍結乾燥血小板および/または請求項3から6の何れか1項に記載の再水和血小板、並びに(b)全血、血漿、または、全血または血漿の成分を含む、インビトロ組成物。
- 新鮮血小板をさらに含む、請求項7の組成物。
- 前記凍結乾燥血小板は再水和されることを特徴とする、請求項7又は8に記載の組成物。
- 前記凍結乾燥血小板又は再水和血小板は、公共の血液供給源から得られたものであることを特徴とする、請求項7から9の何れか1項に記載の組成物。
- 前記凍結乾燥血小板又は再水和血小板は、患者の血液凝固活性に悪影響を及ぼす可能性のある治療を現に受けている、または受けることが予定されている患者から得られたものであることを特徴とする、請求項7から10の何れか1項に記載の組成物。
- 凍結乾燥血小板の調製法であって、
少なくとも1種のサッカライドを含む塩バッファーに血小板を懸濁し、第1組成物を作製すること;
該少なくとも1種のサッカライドが血小板と接触するのに少なくとも十分な時間、第1組成物を、凍結点を超える温度でインキュベートすること;
寒冷保護剤を添加して第2組成物を作製すること、
但し、第1組成物は、寒冷保護剤が添加されるまでは、遠心、またはその他の分離工程を受けることはなく、かつ第1組成物、第2組成物またはその両者は血小板活性化阻害剤を含まない;
第2組成物を凍結乾燥して凍結乾燥血小板を作製すること;および、
前記凍結乾燥血小板を、50℃よりも高い温度で少なくとも10時間加熱することを含む前記方法。 - 前記凍結乾燥血小板を、75℃よりも高い温度で少なくとも18時間加熱することをさらに含むことを特徴とする、請求項12の方法。
- 前記第2組成物に対し、または、前記第1組成物と前記第2組成物の両方に対しエタノールを添加することをさらに含むことを特徴とする、請求項12又は13に記載の方法。
- 前記エタノールは、前記第1組成物には1%(v/v)の量で添加され、前記第2組成物では0.8%の量として存在することを特徴とする、請求項14の方法。
- 前記寒冷保護剤は、ショ糖とエピクロロヒドリンとを共重合させることによって得られるポリマーであって、平均分子量が400,000である前記ポリマーであることを特徴とする、請求項12から15の何れか1項に記載の方法。
- 血小板を準備すること;
100 mMトレハロースおよび1%(v/v)エタノールを含む塩バッファーに血小板を懸濁し、第1組成物を作製すること;
第1組成物を37℃で2時間インキュベートすること;
ショ糖とエピクロロヒドリンとを共重合させることによって得られるポリマーであって、平均分子量が400,000である前記ポリマーを6%(v/v)の最終濃度となるように添加して第2組成物を作製すること;
第2組成物を凍結乾燥して凍結乾燥血小板を作製すること;および、
凍結乾燥血小板を75℃で18時間加熱すること、
を含む請求項12から16の何れか1項に記載の方法。
Applications Claiming Priority (9)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US60083804P | 2004-08-12 | 2004-08-12 | |
US60/600,838 | 2004-08-12 | ||
US61993004P | 2004-10-20 | 2004-10-20 | |
US60/619,930 | 2004-10-20 | ||
US11/152,774 | 2005-06-15 | ||
US11/152,774 US20060035383A1 (en) | 2004-08-12 | 2005-06-15 | Dry platelet preparations for use in diagnostics |
US11/197,310 | 2005-08-05 | ||
US11/197,310 US20060051731A1 (en) | 2004-08-12 | 2005-08-05 | Processes for preparing lyophilized platelets |
PCT/US2005/028559 WO2006020773A2 (en) | 2004-08-12 | 2005-08-12 | Methods for preparing freeze-dried platelets, compositions comprising freeze-dried platelets, and methods of use |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2008509924A JP2008509924A (ja) | 2008-04-03 |
JP2008509924A5 JP2008509924A5 (ja) | 2008-10-02 |
JP5138372B2 true JP5138372B2 (ja) | 2013-02-06 |
Family
ID=35908143
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2007525791A Active JP5138372B2 (ja) | 2004-08-12 | 2005-08-12 | 凍結乾燥血小板の調製法、凍結乾燥血小板を含む組成物、および使用法 |
Country Status (10)
Country | Link |
---|---|
US (1) | US8486617B2 (ja) |
EP (1) | EP1784639B1 (ja) |
JP (1) | JP5138372B2 (ja) |
CN (1) | CN101072506B (ja) |
AT (1) | ATE455463T1 (ja) |
AU (1) | AU2005272821B2 (ja) |
CA (1) | CA2577068C (ja) |
DE (1) | DE602005019064D1 (ja) |
NZ (1) | NZ553389A (ja) |
WO (1) | WO2006020773A2 (ja) |
Families Citing this family (47)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20090035289A1 (en) * | 2005-09-26 | 2009-02-05 | Lifecell Corporation | Dry platelet composition |
US8058064B2 (en) * | 2006-10-04 | 2011-11-15 | The University Of Tokyo | Sac-like structure enclosing hematopoietic progenitor cells produced from ES cells and method for preparing blood cells |
US8372343B2 (en) * | 2007-12-07 | 2013-02-12 | Sheldon Goldstein | Multiple coagulation test cartridge and method of using same |
WO2010022202A1 (en) * | 2008-08-20 | 2010-02-25 | Bio/Data Corporation | Kinetic biologic activity assays and kinetic von willebrand assay |
WO2011124280A1 (en) * | 2010-04-08 | 2011-10-13 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Zeodration method for the preservation of blood platelets |
US9845489B2 (en) | 2010-07-26 | 2017-12-19 | Biomatrica, Inc. | Compositions for stabilizing DNA, RNA and proteins in saliva and other biological samples during shipping and storage at ambient temperatures |
US9376709B2 (en) | 2010-07-26 | 2016-06-28 | Biomatrica, Inc. | Compositions for stabilizing DNA and RNA in blood and other biological samples during shipping and storage at ambient temperatures |
CN101957364A (zh) * | 2010-09-19 | 2011-01-26 | 李勇 | 冻干型血小板抗原谱细胞的制备方法 |
WO2012098358A1 (en) * | 2011-01-20 | 2012-07-26 | Biopharma Technology Ltd | Freeze drying method |
GB201101002D0 (en) * | 2011-01-20 | 2011-03-09 | Biopharma Technology Ltd | Freeze drying method |
EP2508892A1 (de) * | 2011-04-04 | 2012-10-10 | Siemens Healthcare Diagnostics Products GmbH | Kontrollen und Kit für Thrombozytenaktivitätsteste |
CN102327288B (zh) * | 2011-10-17 | 2012-11-14 | 济南环肽医药科技有限公司 | 一种注射用血小板冻干粉制剂及其制备方法 |
US9725703B2 (en) | 2012-12-20 | 2017-08-08 | Biomatrica, Inc. | Formulations and methods for stabilizing PCR reagents |
CA2900851C (en) | 2013-03-15 | 2021-06-22 | Michelle CHUTKA | Ecm implant compositions and methods |
AU2013204728B2 (en) * | 2013-03-15 | 2016-09-15 | Baxalta GmbH | Methods for treating bleeding disorders using a platelet subpopulation |
TW201446253A (zh) * | 2013-06-07 | 2014-12-16 | Chang Gung Medical Foundation Lin Kou Chang Gung Memorial Hospital | 非凝集預活變形血小板之應用及其藥劑 |
CN106572650B (zh) | 2014-06-10 | 2021-08-31 | 生物马特里卡公司 | 在环境温度下稳定凝血细胞 |
JP6687601B2 (ja) * | 2014-08-07 | 2020-04-22 | ザ ジェネラル ホスピタル コーポレイション | 全血サンプルの安定化 |
EP3244901A4 (en) * | 2014-12-31 | 2018-06-20 | Anthrogenesis Corporation | Methods for isolation of platelets |
CN107405391B (zh) * | 2015-03-04 | 2021-03-19 | 罗切斯特大学 | 治疗外伤患者中的出血的血小板微粒的全身和局部应用 |
US20180169139A1 (en) * | 2015-06-10 | 2018-06-21 | Cellphire, Inc. | Composition and methods for treatment of loss of fluids leading to hypotension and/or hypovolemia |
AU2016317642A1 (en) * | 2015-08-28 | 2018-08-16 | Cellphire, Inc. | Products and methods using a platelet-derived hemostatic agent for controlling bleeding and improving healing |
EP4242628A3 (en) | 2015-12-08 | 2023-11-08 | Biomatrica, INC. | Reduction of erythrocyte sedimentation rate |
CN108603853B (zh) * | 2016-02-10 | 2022-08-09 | 索尼公司 | 电特性测量用样本、电特性测量装置和电特性测量方法 |
US20200093853A1 (en) * | 2016-12-08 | 2020-03-26 | Cellphire, Inc. | Compositions and methods for treatment of loss of fluids leading to hypotension and/or hypovolemia |
CN110381962B (zh) * | 2016-12-21 | 2023-10-13 | 孙崇谨 | 用于血浆蛋白的活性保存的新颖方法 |
CA3074712A1 (en) * | 2017-09-13 | 2019-03-21 | Cellphire, Inc. | Canine blood platelet preparations |
CN107998375B (zh) * | 2017-12-14 | 2021-11-05 | 广东医科大学 | 一种多肽在预防或治疗血栓性疾病或脑缺血再灌注损伤相关疾病中的应用 |
EP3887404A4 (en) * | 2018-11-30 | 2022-11-02 | Cellphire, Inc. | SLIDES LOADED WITH ANTI-CANCER AGENTS |
EP3886879A4 (en) | 2018-11-30 | 2022-12-07 | Cellphire Inc. | PLATES AS DELIVERY AGENTS |
WO2020186193A1 (en) * | 2019-03-13 | 2020-09-17 | Cellphire, Inc. | Canine blood platelet preparations |
US10429377B1 (en) | 2019-03-15 | 2019-10-01 | Coagulation Sciences Llc | Coagulation test device, system, and method of use |
SG11202112054WA (en) | 2019-05-03 | 2021-11-29 | Cellphire Inc | Materials and methods for producing blood products |
US20210100846A1 (en) * | 2019-07-17 | 2021-04-08 | Cellphire, Inc. | Use of platelets in treating infections |
EP4013432A4 (en) * | 2019-08-16 | 2023-10-18 | Cellphire Inc. | THROMBOSOMES AS AN ANTICOAGULANT REVERSAL AGENT |
BR112022002892A2 (pt) * | 2019-08-16 | 2022-05-24 | Cellphire Inc | Trombossomos como um agente de reversão de agente antiplaqueta |
CN110585240B (zh) * | 2019-10-10 | 2021-10-29 | 石开生物科技(广州)有限公司 | 一种含再生因子的冻干制剂及其制备方法和应用 |
WO2021108538A1 (en) * | 2019-11-27 | 2021-06-03 | Cellphire, Inc. | PLATELETS LOADED WITH mRNA |
WO2021158622A1 (en) | 2020-02-04 | 2021-08-12 | Cellphire, Inc. | Anti-fibrinolytic loaded platelets |
WO2021232015A1 (en) | 2020-05-15 | 2021-11-18 | Cellphire, Inc. | Platelet derived extracellular vesicles |
CN113156144A (zh) * | 2021-01-29 | 2021-07-23 | 郑州普湾医疗技术有限公司 | 一种血小板聚集功能花生四烯酸杯检测试剂及其制备方法 |
WO2022178191A1 (en) | 2021-02-17 | 2022-08-25 | Cellphire, Inc. | Freeze-dried platelet derivative compositions for treating anticoagulant-induced coagulopathy |
WO2022178177A1 (en) | 2021-02-17 | 2022-08-25 | Cellphire, Inc. | Freeze-dried platelet derivative compositions for treating antiplatelet-induced coagulopathy |
EP4086634A1 (en) * | 2021-05-06 | 2022-11-09 | Eberhard Karls Universität Tübingen Medizinische Fakultät | Method for diagnosing a predisposition of a living being to develop thrombocytopenia |
WO2023081804A1 (en) | 2021-11-04 | 2023-05-11 | Cellphire, Inc. | Platelet derivative compositions, and methods of making and using such compositions |
WO2023220694A1 (en) | 2022-05-12 | 2023-11-16 | Cellphire, Inc. | Mri-agent loaded platelet compositions and methods of preparing and using the same |
WO2023220739A1 (en) | 2022-05-12 | 2023-11-16 | Cellphire, Inc. | Platelet derivative compositions for use in subjects afflicted with hermansky pudlak syndrome or bernard soulier syndrome |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5213814A (en) | 1989-04-10 | 1993-05-25 | Cryopharm Corporation | Lyophilized and reconstituted blood platelet compositions |
EP0642301B1 (en) | 1992-05-29 | 2003-03-12 | The University Of North Carolina At Chapel Hill | Pharmaceutically acceptable fixed-dried human blood platelets |
US5656498A (en) | 1994-02-22 | 1997-08-12 | Nippon Telegraph And Telephone Corporation | Freeze-dried blood cells, stem cells and platelets, and manufacturing method for the same |
JP3788522B2 (ja) * | 1994-02-22 | 2006-06-21 | 日本電信電話株式会社 | 血球、幹細胞、および血小板の凍結乾燥生成物の製造方法 |
JPH09109136A (ja) | 1995-10-16 | 1997-04-28 | Mitsubishi Materials Corp | モルタル又はコンクリートの製造装置 |
US5736313A (en) | 1995-10-20 | 1998-04-07 | The United States Of America As Represented By The Secretary Of The Navy | Method of lyophilizing platelets by incubation with high carbohydrate concentrations and supercooling prior to freezing |
CA2256333A1 (en) | 1996-05-29 | 1997-12-04 | Victor Bronshtein | Long-term shelf preservation by vitrification |
EP0967862B1 (en) | 1997-02-07 | 2003-01-15 | Elan Drug Delivery Limited | Methods and compositions for producing dried, storage-stable platelets |
US6211575B1 (en) * | 1999-08-18 | 2001-04-03 | Sigmatel Inc. | Method and apparatus for identifying customized integrated circuits |
US20020076445A1 (en) | 2000-02-10 | 2002-06-20 | Crowe John H. | Eukaryotic cells and method for preserving cells |
AU2001234978A1 (en) * | 2000-02-10 | 2001-08-20 | The Regents Of The University Of California | Therapeutic platelets and methods |
US6653062B1 (en) | 2000-07-26 | 2003-11-25 | Wisconsin Alumni Research Foundation | Preservation and storage medium for biological materials |
US20050074402A1 (en) | 2000-10-19 | 2005-04-07 | Aldo Cagnolini | Radiopharmaceutical formulations |
WO2004050896A2 (en) | 2002-11-29 | 2004-06-17 | The Regents Of The University Of California | A method and therapeutic platelets |
-
2005
- 2005-08-12 AU AU2005272821A patent/AU2005272821B2/en active Active
- 2005-08-12 JP JP2007525791A patent/JP5138372B2/ja active Active
- 2005-08-12 DE DE602005019064T patent/DE602005019064D1/de active Active
- 2005-08-12 CA CA2577068A patent/CA2577068C/en active Active
- 2005-08-12 EP EP05784165A patent/EP1784639B1/en active Active
- 2005-08-12 NZ NZ553389A patent/NZ553389A/en unknown
- 2005-08-12 US US11/659,708 patent/US8486617B2/en active Active
- 2005-08-12 WO PCT/US2005/028559 patent/WO2006020773A2/en active Application Filing
- 2005-08-12 CN CN2005800348733A patent/CN101072506B/zh active Active
- 2005-08-12 AT AT05784165T patent/ATE455463T1/de active
Also Published As
Publication number | Publication date |
---|---|
WO2006020773A3 (en) | 2007-07-12 |
US8486617B2 (en) | 2013-07-16 |
ATE455463T1 (de) | 2010-02-15 |
CN101072506A (zh) | 2007-11-14 |
EP1784639B1 (en) | 2010-01-20 |
CA2577068C (en) | 2016-05-17 |
WO2006020773A2 (en) | 2006-02-23 |
EP1784639A2 (en) | 2007-05-16 |
DE602005019064D1 (de) | 2010-03-11 |
NZ553389A (en) | 2009-10-30 |
US20070243178A1 (en) | 2007-10-18 |
CA2577068A1 (en) | 2006-02-23 |
CN101072506B (zh) | 2010-05-12 |
EP1784639A4 (en) | 2008-05-07 |
AU2005272821A1 (en) | 2006-02-23 |
JP2008509924A (ja) | 2008-04-03 |
AU2005272821B2 (en) | 2010-09-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5138372B2 (ja) | 凍結乾燥血小板の調製法、凍結乾燥血小板を含む組成物、および使用法 | |
US7811558B2 (en) | Use of stabilized platelets as hemostatic agent | |
US20060051731A1 (en) | Processes for preparing lyophilized platelets | |
US20060035383A1 (en) | Dry platelet preparations for use in diagnostics | |
US8097403B2 (en) | Freeze-dried platelets, method of making and method of use as a diagnostic agent | |
US7285266B2 (en) | Cell-polymer fiber compositions and uses thereof | |
EP1338648B1 (en) | Pharmaceutically acceptable fixed-dried human blood platelets | |
US20110183311A1 (en) | Dry platelet preparations for use in diagnostics | |
US20200291356A1 (en) | Canine blood platelet preparations | |
Abonnenc et al. | In vitro evaluation of pathogen-inactivated buffy coat-derived platelet concentrates during storage: psoralen-based photochemical treatment step-by-step | |
US20230112136A1 (en) | Canine blood platelet preparations | |
WO2017177104A1 (en) | Reconstitution solution for spray-dried plasma | |
Price et al. | Platelet‐enhanced plasma: Characterization of a novel candidate resuscitation fluid's extracellular vesicle content, clotting parameters, and thrombin generation capacity | |
van Hezel et al. | The effect of red blood cell transfusion on platelet function in critically ill patients | |
Smith et al. | Procoagulant phospholipid concentration in canine erythrocyte concentrates stored with or without prestorage leukoreduction | |
US20190255114A1 (en) | Storage of platelets | |
RU2485502C1 (ru) | Способ оценки морфофункционального статуса тромбоцитов человека | |
AU2017367084B2 (en) | RMP composition and methods of use | |
US20170370952A1 (en) | Reconstitution Solution for Spray-Dried Plasma | |
BR102021018145A2 (pt) | Biofármaco rico em fatores de crescimento liofilizados e processo de produção | |
Tissot | In vitro evaluation of pathogen-inactivated buffy coat-derived platelet concentrates during storage: psoralen-based photochemical treatment step-by-step | |
JP2001131078A (ja) | 新規活性固定化血小板及びその製造方法 | |
Fontenot | Tube centrifugation for processing platelet-rich plasma in the horse |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A711 | Notification of change in applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A711 Effective date: 20080616 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20080616 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20080808 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20080808 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20110823 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20111116 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20111124 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20111220 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20111228 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20120118 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20120125 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20120223 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20121023 |
|
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20121114 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 5138372 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20151122 Year of fee payment: 3 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |